CA2353462A1 - Molecular scaffolds acting as templates comprising carbamate linkages - Google Patents

Molecular scaffolds acting as templates comprising carbamate linkages Download PDF

Info

Publication number
CA2353462A1
CA2353462A1 CA002353462A CA2353462A CA2353462A1 CA 2353462 A1 CA2353462 A1 CA 2353462A1 CA 002353462 A CA002353462 A CA 002353462A CA 2353462 A CA2353462 A CA 2353462A CA 2353462 A1 CA2353462 A1 CA 2353462A1
Authority
CA
Canada
Prior art keywords
compound
group
carbon atoms
groups
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002353462A
Other languages
French (fr)
Inventor
David S. Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/457,607 external-priority patent/US6458953B1/en
Application filed by Individual filed Critical Individual
Publication of CA2353462A1 publication Critical patent/CA2353462A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/69—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Abstract

This invention pertains generally to valency molecules, such as valency platform molecules which act as scaffolds to which one or more molecules may be covalently tethered to form a conjugate. More particularly, the present invention pertains to valency platform molecules which comprise a carbamate linkage (i.e., -O-C(=O)-N~). In one aspect, the present invention pertains t o valency platforms comprising carbamate linkages, which molecules have the structure of any one of Formulae I, II, or III, shown in Figure (1). In one aspect, the present invention pertains to valency platforms comprising carbamate linkages, which molecules have the structure of any one of Formula e IV, V, or VI, shown in Figure (8). The present invention also pertains to methods of preparing such valency platform molecules, conjugates comprising such valency platform molecules, and methods of preparing such conjugates.</ SDOAB>

Description

MOLECULAR SCAFFOLDS ACTING AS TEMPLATES COMPIltISING CARBAMATE LINKAGES
TECHNICAL FIELD
This invention pertains generally to valency molecules. The invention also relates I O to the field of valency platform molecules which act as scaffolds to which one or more molecules may be covalently tethered to form a conjugate. More particularly, the present invention pertains to valency molecules which comprise a carbamate linkage (z.e., -O-C(=O)-N<). In one aspect, the present invention pertains to valency platforms comprising carbamate linkages, which molecules have the structure of any one of Formulae I, II, or III, shown in Figure 1. In one aspect, the present invention pertains to valency platforms comprising carbamate linkages, which molecules have the structure of any one of Formulae IV, V, or VI, shown in Figure 8. The present invention also pertains to methods of preparing such valency molecules, conjugates comprising such valency molecules, and methods of preparing such conjugates.

BACKGROUND
A "valency platform" is a molecule with one or more (and typically multiple) attachment sites which can be used to covalently attach biollogically active molecules of interest to a common scaffold. The attachment of biologically active molecules to a common scaffold provides multivalent conjugates in which multiple copies of the biologically active molecule are covalently linked to the same platform. A
"defined" or "chemically defined" valency platform is a platform with df;fined structure, thus a defined number of attachment points and a defined valency. A defined valency platform conjugate is a conjugate with defned structure and has a defined number of attached biologically active compounds. Examples of biologically active molecules include oligonucleotides, peptides, polypeptides, proteins, antibodies, saccharides, polysaccharides, epitopes, mimotopes, drugs, and the like. In general, biologically active compounds interact specifically with proteinaceous receptors.
Certain classes of chemically defined valency platforms, methods for their preparation, conjugates comprising them, and methods for tlhe preparation of such conjugates, have been described in the U.S. Patents Nos. 5,1.62,515;
5,391,785; 5,276,013;
5,786,512; 5,726,329; 5,268,454; 5,552,391; 5,606,047; andl 5,663,395.
The valency platforms of the present invention reflect a new class of valency platforms which comprise a carbamate linkage, as shown, for example, in Formulae I, II, and III in Figure 1 and in Formulae IV, V, and Vi in Figure 8.
SUMMARY OF THE INVENTION
One aspect of the present invention pertains to a vale:ncy platform compound having the structure of one of the following formulae:
Formula I

R~ J-w~ IC-N C~-O-Z
y' RN
2_y, Formula II

R~ J-'C-N G~-O-CI-N C~2--O-Z
N 2 ~ 1 [ RN ] 2_Y Y
2_Y~
Formula III

R~ J-IC-N G'-O-IC-N G2-O-IC-IV G3-O-Z
I N ~ Y3 RN ~ 2_Ya Y2 RN ~ 2_Y2 Y~
2_Y~
wherein:
n is a positive integer from 1 to 10;
y' , yz, and y3 are independently 1 or 2;
J independently denotes either an oxygen atom or a covalent bond;
R~ is selected from the group consisting of:
hydrocarbyl groups having from 1 to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms;
organic groups consisting oiZly of carbon, oxygen, nitrogen, and hydrogen atoms, and having from 1 to 20 carbon .atoms;
organic groups consisting only of carbon, oxygen, sulfur, and hydrogen atoms, and having from 1 to 20 carbon atoms;
each G', G2, and G3 is independently selected from the group consisting of:
hydrocarbyl groups having from 1 to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, nitrogen, and hydrogen atoms, and having from 1 to 20 carbon atoms;
each RN is independently selected from the group consisting of:
hydrogen;
linear or branched alkyl groups having from I to 15 carbon atoms;
alkyl groups comprising an alicyclic structure and having from 1 to 15 carbon atoms;
aromatic groups having from 6 to 20 carbon atoms;
heteroarornatic groups having from 3 to 20 carbon atoms;
each Z is independently selected from the group consisting of:
-H
-C(=O)OR~''~
-C(=O)RES~R
-C(=O)NR"Ra wherein:
each R~~~ is organic groups comprising from 1 to about 20 carbon atoms;
each RES'~~ is organic groups comprising from 1 to about 20 carbon atoms;
each group -NR"Rg is independently selected from the group consisting of:
-NHz -NHRA
-NR"RB
-NR'°'B
wherein each monovalent R" and R~ and each divalent R'~ is independently an organic group comprising from:I to 20 carbon atoms, and further comprising a reactive conjugating functional group.
In one embodiment, said compound has the structure of Formula I. In one embodiment, said compound has the structure of Formula II. In one embodiment, said compound has the structure of Formula III. In one embodiment, said compound has the structure of Formula IV. In one embodiment, n is a positive integer from 2 to 4. In one embodiment, y' , yz, and y3 are each 2. In one embodiment, J is an oxygen atom. In one embodiment, J is a covalent bond. In one embodiment, R~ is selected from the group consisting of hydrocarbyl groups having from 1 to 20 carbon atoms. In one embodiment, R~ is selected from the group consisting of:
-CHZ-;
-CHZCHZ-;
-CHZCHZCHz-;
i H2 :,and \ /
In one embodiment, R~ is selected from the group consisting of organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having fi.°om 1 to 20 carbon atoms. In one embodiment, R~ is:
cH2-cH2-o cw2--cH2-p-1 wherein p is a positive integer from 2 to 20. In one embodiment, each G', G'-, and G3 is independently selected from the group consisting of hydrocarbyl groups having from 1 to carbon atoms. In one embodiment, each G', GZ, and G3 is -(CHZ)q wherein q is a positive integer from 1 to 20. In one embodiment, each G'; GZ, and G3 is independently selected from the group consisting of organic groups consisting only of carbon, oxygen, 20 and hydrogen atoms, and having from 1 to 20 carbon atoms. In one embodiment, each G', Gz, and G3 is:

p-1 S

wherein p is a positive integer from 2 to 20. In one embodiment, R~' is independently selected from the group consisting of -H, -CH3, and -CHZC'.H3. In one embodiment, each group -NRARB is independently selected from the group consisting of 'N-H
II

--N 'NH.HBr O
-N\ N-C-CH2-X
~'NH~CH2~NHz ~n -NH-CH2CH2-NH-~-O--C-CH3 cH3 and -NH~cH2cH2o~cH2cH2--NHZ
Another aspect of the present invention pertains to a valency platform compound having the structure of one of the following formulae:
Formula iV

R~ d-IC-N-G' O-Z
Y~
RN

Formula V

Rc J-C-N-Gt O-IC-N-Gz O-Z
N N
yt Formula VI

R~ ~_"'IC-N-Gi O-IC-N-Gz O-1C-N,_G3 ,O-Z

wherein:
n is a positive integer from 1 to 10;
y' , yz, and y3 are independently a positive integer i:rom 1 to 10;
J independently denotes either an oxygen atom or a covalent bond;
R~ is selected from the group consisting of hydrocarbyl groups having from I to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, and hydrogen atoms, and I O having from I to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, nitrogen, and hydrogen atoms, and having from 1 to 20 carbon ;atoms;
organic groups consisting only of carbon, oxygen, sulfur, and hydrogen atoms, and having from 1 to 20 carbon atoms;
15 each G', Gz, and G3 is independently selected from the group consisting of hydrocarbyl groups having from 1 to 20 carbon. atoms;
organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, nitrogen, and hydrogen 20 atoms, and having from I to 20 carbon atoms;
each R~' is independently selected from the group consisring of hydrogen;
linear or branched alkyl groups having from 1 to 15 carbon atoms;
alkyl groups comprising an alicyclic structure and having from 1 to 15 carbon atoms;
aromatic groups having from 6 to 20 carbon atoms;
heteroaromatic groups having from 3 to 20 carbon atoms;
each Z is independently selected from the group consisting of:
-H
-C(=O)OR~
-C(=O)RESrsR
-C(=O)NR~RB
wherein:
each Rc"~ is organic groups comprising from 1 to about 20 carbon atoms;
each RES~R is organic groups comprising from 1 to about 20 carbon atoms;
1 S each group -NRARB is independently selected from the group consisting of -NHZ
-NHR"
-NRARB
-NR"~
wherein each monovalent R" and R~ and each divalent R"B is independently an organic group comprising from 1 to 20 carbon atoms, and further comprising a reactive conjugating functional group.
In one embodiment, said compound has the structure ofFormula V. In one embodiment, said compound has the structure of Formula VI. In one embodiment, said compound has the structure of Formula VII. In one embodiiment, n is a positive integer from 2 to 4. In one embodiment, yl , yz, and y3 are each 2. In one embodiment, J is an oxygen atom. In one embodiment; d is a covalent bond. In one embodiment, RC is selected from the group consisting of hydrocarbyl groups having from 1 to 20 carbon atoms. In one embodiment, R~ is selected from the group consisting of _CHz_~

WO 00!34231 PCT/US99/29339 -CHZCHz-;
-CH2CH2CH2-;
i H2 -CHZ- i -CH2 ...~.- ; and v i ~
In one embodiment, R~ is selected from the group consisting of organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having from I to 20 carbon atoms. In one embodiment, R~ is:
CH2.-CH2..-p CH2-, CH2-p-1 wherein p is a positive integer from 2 to 20. In one embodiment, each G', Gz, and G3 is independently selected from the group consisting of hydrocarbyl groups having from I to carbon atoms. In one embodiment, each G', G2, and G3 its selected from the group consisting of:
IH2.-~ IH2-~ lti2-~'-~H ~-i-CHs ~-i-CH2CN3 CHZ- ~ CH2- ~ and Cti2 In one embodiment, each G', Gz, and G3 is independently selected from the group 1 S consisting of organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms. In one embodiment, each RN is independently selected from the group consisting of -H, -CH3, and -CHZCH~. In one embodiment, each group -NR"RB is independently selected from the group consisting; of:
"'-N \N-H
O
20 ~ - ~N-C-o-cH2----N \NH.Hl3r -N\ /N-C-CH2-X
-NH~ CHz~Nld2 Jn -NH-CH2CH2-NW-C!-O__C_CH3 i cH~ ~d -NH-f-CH2CH20-f-CH2CIH2-NH2 /n Another aspect of the present invention pertains to methods of preparing a valency platform compound, as described herein.
Another aspect of the present invention pertains to a conjugate comprising a valency platform compound, as described herein, covalently linked to one or more biologically active molecules. In one embodiment, said biologically active molecules are selected from the group consisting of oligonucleotides, peptides, polypeptides, proteins, antibodies, saccharides, polysaccharides, epitopes, mimotopes, and dnigs.
Another aspect of the present invention pertains to methods of preparing conjugates, as described herein.
As will be appreciated by one of skill in the art, feal;ures of one aspect or embodiment of the invention are also applicable to other aspects or embodiments of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows certain valency platforms of the present invention, specifically, those having the structure of Formulae I, II, and III.
Figure 2 shows certain valency platforms of the present invention, specifically, some of those having the structure of Formula I.
Figure 3 shows certain valency platforms of the present invention, specif cally, some of those having the structure of Formula I.
Figure 4 shows certain vaiency platforms of the present invention, specifically, some of those having the structure of Farrnula II.
Figure 5 shows certain valency platforms of the present invention, specifically, some of those having the structure of Formula II.
Figure 6 shows certain valency platforms of the present invention, specifically, some of those having the structure of Formula III.
1 S Figure 7 shows certain valency platforms of the present invention, specifically, some of those having the structure of Formula I.
Figure 8 shows certain valency platforms of the present invention, specifically, those having the structure of Formulae VI, V, and VI.
Figure 9 shows a synthetic scheme for a simple example of "care propagation"
to obtain valency platforms of the present invention.
Figure I O shows synthetic schemes for the preparation of certain intermediates useful in the preparation of valency platforms of the present; invention.
Figures 1 lA and 1 IB show synthetic schemes for the preparation of valency platform molecules of the present invention.
Figures 12A and 12B show synthetic schemes for the preparation of valency platform molecules of the present invention.
Figure 13 shows a synthetic schemes for the preparation of valency platform molecules of the present invention.
Figures 14A and 14B show synthetic schemes for the preparation of valency platform molecules of the present invention.

Figure 15 shows a synthetic schemes far the preparation of vaiency platform molecules of the present invention.
Figures 16A and 16B show synthetic schemes for the preparation of valency platform molecules of the present invention.
Figures 17A, 17B, 17C, and 17D show synthetic schemes for the preparation of valency platform molecules of the present invention.
Figures 18A and 18B show synthetic schemes for tile preparation of valency platform molecules of the present invention.
Figure i 9 shows a synthetic schemes for the preparation of valency platform molecules of the present invention.
Figures 20A and 20B show synthetic schemes for the preparation of valency platform molecules of the present invention.
Figure 21 shows the structure of examples of two c~~rbamate compounds 39b and 39c.
DETAILED DESCRIPTION OF THE INVENTION
Throughout this application, various publications, patents, and published patent applications are referred to by an identifying citation. The disclosures of the publications, patents, and published patent specifications referenced in this application are hereby incorporated by reference into the present disclosure in their entirety.
In one embodiment, valency molecules are provided that comprise branches, wherein at each branch, the molecule branches into two or more arms. The arms also may comprise branches. The valency molecule further comprises terminal groups on arms extending from the branches. Exemplary terminal groups are reactive conjugating functional groups. This is illustrated in the Figures, for exarnple, by compound _14 in Figure 11B, which includes 6 branches and 8 terminal CBZ-protected amino groups.
Thus, in one embodiment, provided is a composition comprising valency molecules, wherein each valency molecule comprises at least two branches, ~at least four terminal groups, and at least 2 carbamate linkages; and wherein said valency molecules have a polydispersity less than about I.2, or for example, less than about 1.07. The valency molecules further can comprise, for example, at least 4 carlbamate linkages, at least 4 branches and at least 8 terminal groups. The valency molecules rnay be dendrimers.
The number of branches in the valency molecule may vary and may be, for example, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 16, 32, 64, 100 or more branches.
The number of branches can be, for example, 2-64, 2-32, 2-16, 4-64, 4-32, 8-64, or $-32. In a further embodiment, the number of branches may be, for example, at least 2, at least 4, at least 6, or at least 8.
The number of carbamate linkages may vary. The valency molecule can include, for example, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 15, 16, 18, 20, 24~, 29, 32, 64, 100 or more carbamate linkages. The number of carbaxnate linkages can be, for example, 2-64, 2-32, 2-16, 4-64, 4-32, 8-64, or 8-32. In a further embodiment, the number of carbamate linkages may be, for example, at least 2, at least 4, at least 6, or at least 8.
Each valency molecule can comprise for example, 1 to 100, e.g, 1-SO terminal groups. For example, the valency molecule may comprise 4, 6, 8, 9, 10, I2, 14, 15, 16, 18, 20, 21, 24, 29, or 32 or more terminal groups. The valency molecule, for example, may comprise at least 4 terminal groups, or at least 6 terminal groups, or at least 8 terminal groups. The valency molecule in one embodiment has, for example, 4-16, 4-32, 4-64, 8-32, 8-64, 12-32 or 12-64 terminal groups. The said terminal groups are in one embodiment identical.
Examples of valency molecules include valency platform molecules. Valency molecules can be made as described herein for the synthesis of valency platform molecules.

A. Valency Platforms In one aspect, the present invention pertains to valE;ncy platforms comprising carbamate linkages and methods for the preparation of such platforms.
Particular advantages of the present invention include, but are not limited to, ( I ) the ease of synthesis of valency platform molecules, (2) the metabolic stability of the carbamate linkages in the valency platform, (3) the ability to adjust the length and water solubility of the "arms" of the valency platform by using, i:or example, different dialcoholamines, (4) the ability to further attenuate the properties of the valency platform by choice of the core group (e.g., attachment of solubilizing groups, chromophores, reporting groups, targeting groups, and the like).
In one embodiment, a composition is provided comprising valency platform I 5 molecules, wherein each valency platform molecule comprises at least 2 carbamate linkages and at least 4 reactive conjugating functional groups; and wherein said valency platform molecules have a polydispersity less than about I "2, or optionally a polydispersity less than about 1.07. The valency platform molecules of the composition may comprise, for example, at least 4 carbamate linkages and at least 8 reactive functional groups. In one embodiment, the valency platform molecules comprise at least 4 identical reactive conjugating functional groups. In another embodiment, the; valency platform molecules comprise, for example, 232 carbamate linkages and 4-64 reactive functional groups. The valency platform molecules optionally may be linked to one or more biologically active molecules, e.g., via the reactive conjugating functional groups.
The valency molecules, such as valency platform molecules have the advantage of having a substantially homogeneous (i. e., uniform) molecular weight (as opposed to polydisperse molecular weight), amd are thus "chemically defined".
Accordingly, a population of these molecules (or conjugates thereof) are substantially monodisperse, i. e., have a narrow molecular weight distribution. A measure of the breadth of distribution of molecular weight of a sample of a platform molecule (such as a composition and/or population of platform molecules) is the polydispersity of the sample.
Polydispersity is used as a measure of the molecular weight homogeneity or nonhomogeneity of a polymer sample. Polydispersity is calculated by dividing the weight average molecular weight (Mw) by the number average molecular weight (Mn). The. value of Mw/Mn is unity for a perfectly monodisperse polymer. Polydispersity (Mw/Mn;) is measured by methods available in the art, such as gel permeation chromatography. The polydispersity (Mw/Mn) of a sample of valency molecules is preferably less than 2, more preferably, less than 1.5, or less than I.2, Less than l.l, less than I .07, less than 1.02, or, e.g., about 1.05 to 1.5 or about 1.05 to I .2. Typical polymers generally have a polydispersity of 2-5, or in some cases, 20 or more. Advantages of the law polydispersity property oi~the valency platform molecules include improved biocompatibility and bioava.ilability since the molecules are substantially homogeneous in size, and variations in biological activity due to wide variations in molecular weight are minimized. The low polydispersity molecules thus are pharmaceutically optimally formulated and easy to analyze;.
Further there is controlled vaIency in a population of the valency molecules.
Thus, in a population of valency platform molecules, for example, the number of attachment sites, e.g., reactive conjugating functional groups, is controlled a.nd defined. Each valency platform molecule can comprise for example, I to 100, e.g, 1-50 attachment sites. For example, the valency platform molecule may comprise 4, fi, 8, 9, 10, 12, 14, 15, 16, 18, 20, 21, 24, 29, or 32 or more attachment sites. The valency platform molecule, for example, may comprise at Least 4 attachment sites, or at least 6 atta.clhment sites, or at least 8 attachment sites. The valency platform molecule in one ennbodiment has, for example, 4-16, 4-32, 4-64, 8-32, 8-64, 12-32 or 12-64 attachment sites. The said attachment sites are in one preferred embodiment identical.
The number of earbamate linkages may vary. The valency platform molecule can include, for example, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 15, 16, 1.8, 20, 24, 29, 32, 64, 100 or more carbamate linkages. The number of carbamate Linkages can be, for example, 2-64, 2-32, 2-16, 4-64, 4-32, 8-64, or 8-32. In a further embodiment, the number of carbamate Linkages may be, for example, at least 2, at least 4, at least ~6, or at least 8.
IS

The valency platform molecule can comprise various combinations of the carbamate linkages and attachment sites such as reactive functional groups depending on the method of preparation, for example, 2-32 , e.g., 2-if carbamate linkages; and 4-64;
e.g., 4-32 reactive functional groups.
Formula I
In one embodiment, the present invention pertains. to a valency platform having the structure of Formula I, as shown in Figure 1.
Formula I

R~ J--IC-N G~-fl__Z
Yi 2-y' n In Formula I, n is a positive integer from 1 to 10, snore preferably from 1 to 5. In one embodiment, n is a positive integer from 2 to 10, more preferably from 2 to 5. In one 1 S embodiment, n is 1. In one embodiment, n is 2. In one embodiment, n is 3.
In one embodiment, n is 4.
In Formula I, y' is I or 2, and the subscript "2-y'" its therefore I or 0, respectively.
In Formula I, J independently denotes either an oxygen atom (i.e., -O-) or a covalent bond (i.e., no atom is present). When J is -O-, R~ is bound to the corresponding sidechain via a carbamate linkage {i.e., -O-C(=O)-N<). When J is a covalent bond, R~ is bound to the corresponding sidechain via an amide linkage (i.e., -C(=O;I-N<).
In Formula I, R~ denotes a "core group," that is, an organic group which forms the core of the valency platform, and to which one or more sid.echains is attached. The valency WO 00/34231 PCTlUS99/29339 of the core group is determined by n. If n is 1, then R~ is rnonovalent; if n is 2, then Rc is divalent; if n is 3, then RC is trivalent; if n is 4, then RC is tetravalent, and so on.
In one embodiment, RC is a hydrocarbyl group (i.e., consisting only of carbon and hydrogen) having from 1 to 20 carbon atoms, more preferably from 1 to 10 carbon atoms, still more preferably from 1 to 6 carbon atoms. In one embodiment, RC is linear. In one embodiment, R~ is branched. In one embodiment, R~ com;prises a cyclic structure. In one embodiment, R~ is cyclic. In one embodiment, R~ is fully saturated. In one embodiment, R~ is partially unsaturated. In one embodiment, R~ comprises an aromatic structure. in one embodiment, R~ is aromatic. In one embodiment, Rc is -CH2-. In one embodiment, R~ is -CH~CH,-. In one embodiment, R~ is -CHZCHZCHZ-. In one embodiment, R~ is:
f Hz -CH2- i -CH2 In one embodiment, R~ is:
v i ~
is In one embodiment, R~ is an organic group consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms, mare preferably from 1 to 10 carbon atoms, still more preferably from 1 to 6 carbon atoms. In one embodiment, R~ is derived from a polyalkylene oxide group. In one embodiment, R~ is derived from a polyethylene oxide group. In one embodiment, R~ is a divalent polyalkylene oxide group.
In one embodiment, R~ is a divalent polyethylene oxide group. In one embodiment, R~ is a divalent polypropylene oxide group. In one embodiment, R~ is:

wherein p is a positive integer from 2 to about 200, rnore preferably from 2 to about 50, more preferably from 2 to about 20, more preferably from 2 to about 10, more preferably from 2 to about b. In one embodiment, p is 2. In one embodiment, p is 3. In one embodiment, p is 4. In one embodiment, p is 5. In one embodiment, p is 6.
In one embodiment, R~ is an organic group cansi;;ting only of carbon, oxygen, nitrogen, and hydrogen atoms, and having from 1 to 20 carbon atoms, more preferably from 1 to 10 carbon atoms, still more preferably from 1 to 6 carbon atoms. Examples of such core groups include, but are not limited to, those derive from the "core compounds"
described below which consist only of carbon, oxygen, nitrogen, and hydrogen atoms.
In one embodiment, Rc is an organic group consisting only of carbon, oxygen, sulfur, and hydrogen atoms, and having from 1 to 20 carbon atoms, more preferably from 1 to 10 carbon atoms, still more preferably from 1 to 6 carbon atoms. Examples of such core groups include, but are not limited to, those derive from tJhe "core compounds" described below which consist only of carbon, oxygen, sulfur, and hydrogen atoms.
In Formula I, G' denotes an organic "linker group,." In one embodiment, G' is a hydrocarbyl group {i. e., consisting only of carbon and hydrogen) having from I to 20 caxbon atoms, more preferably from 1 to 10 carbon atoms, still more preferably from 1 to carbon atoms. In one embodiment, G' is linear. In one ernbadiment, G' is branched. In one embodiment, G' comprises a cyclic structure. In one embodiment, G' is cyclic. In one embodiment, G' is fully saturated. In one embodiment, G' is partially unsaturated. In one embodiment, G' comprises an aromatic structure. In one embodiment, G' is aromatic. In one embodiment, G' is divalent. In one embodiment, RC i.s -{CHZ)q wherein q is a positive integer from 1 to about 20, more preferably from 1 to about 10, more preferably from 1 to about 6, more preferably from 1 to about 4. In one embodiment, G' is -CFIz-.
In one embodiment, G' is -CHZCHZ-. In one embodiment, G' is -CHZCHzCH2-.
In one embodiment, G' is an organic group consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms, rxrore preferably from 1 to I O
carbon atoms, still more preferably from 1 to 6 carbon atoms. In one embodiment, G' is derived from a polyalkylene oxide group. In one embodiment, G' is a divalent polyalkylene oxide group. In one embodiment, G' is a divalent polyethylene oxide group.
In one embodiment, G' is a divalent polypropylene oxide group. In one embodiment, G' is:

p-1 wherein p is a positive integer from 2 to about 200, more preferably from 2 to about 50, more preferably from 2 to about 20, more preferably from 2 to about 10, more preferably from 2 to about b. In one embodiment, p is 2. In one embodiment, p is 3. In one embodiment, p is 4. In one embodiment, p is 5. In one; embodiment, p is 6.
In one embodiment, G' is an organic group consisting only of carbon, oxygen, I O nitrogen, and hydrogen atoms, and having from 1 to 20 carlbon atoms, more preferably From I to 10 carbon atoms, still more preferably from I to 6 carbon atoms.
In Formula I, RN denotes a nitrogen substituent, moue specifically, an amino substituent. In one embodiment R~', if present, is hydrogen (i.e., -H). In one embodiment, R~', if present, is a linear or branched alkyl group having from I to I S
carbon atoms, more preferably from 1 to 10 carbon atoms, more preferably from I to 6 carbon atoms. In one embodiment, RN, if present, is an alkyl group comprising an alicyciic structure and having from I to I 5 carbon atoms, more preferably from 1 to 10 carbon atoms, more preferably from I to 6 carbon atoms. In one embodiment, RN, if present, is or comprises an aromatic group. In one embodiment, RN, if present, is or comprises a~ heteroaromatic group. In one embodiment, RN, if present, is or comprises an aromatic group having from 6 to 20 carbon atoms, more preferably from b to 1 S carbon atoms, more preferably from 6 to I0 carbon atoms. In one embodiment, RN, if present, is or comprises a heteroarornatic group having from 3 to 20 carbon atoms, more preferably from 3 to 1 S carbon atoms, more preferably from 3 to I0 carbon atoms. In one embodiment, R~ is selected from the group consisting of -H, -CH,, and -CH,CH3.
In Formula I, Z denotes a terminal group, which is independently selected from the group consisting of: -H (which yields a terminal alcohol group), -C(=O)ORc~'~
(which i9 yields a terminal carbonate group), -C(=O)RES~ (which yield a terminal ester group), and -C{=O)NR"RB {which yields a terminal carbamate group).
In the above formulae, each -Rc~'~ is a carbonate substituent or an activated carbonate substituent. Many carbonate substituents are well known in the art, including, for example, organic groups comprising from 1 to about 20 carbon atoms, including, for example, primary, secondary, and tertiary, substituted and unsubstituted, alkyl and aryl groups having from I to about 20 carbon atoms. Other examples of carbonate groups include those described herein for Rte. Still other examples of carbonate groups include those described below for activated carbonates.
In the above formulae, each RES~R is an ester substituent or an activated ester substituent. Many ester and activated ester substituents are well known in the art, including, for example, organic groups comprising from 1 to about 20 carbon atoms, including, for example, primary, secondary, and tertiary alkyl and aryl groups having from 1 to about 20 carbon atoms. Other examples of carbonate groups include those described herein for RN. Examples of R~s~R include, but are not limited to, -CH3 (ta give an acetate group), -CH~SH (to give a mercaptoacetate group), and -C:HZC6H5, to give a benzoate group).
In one embodiment, Z is -NR"RH and denotes an amino group. The amino group may be unsubstituted, in which case, R~ and RB are both hydrogen (i. e., -NR"R$ is -NHZ).
The amino group may be monosubstituted, in which case R$ is hydrogen (i.e., -NR"RH is -NHRA). The anuno group may be disubstituted. In this case, RA and R$ may be separate moieties, as in -NR"RB, or R" and RB may be covalently linked together and form a divalent substituent, denoted R~ (i.e., -NR"RB is -NR"g). Thus, in one embodiment, each group -NRARH is independently selected from the group consisting; of -NHZ, -NHRA, -NHR"RB, and -NR's, wherein each monovalent R~ and RB and each divalent R'~ is independently an organic group comprising from 1 to 20 carbon atoms, and :further comprising a reactive conjugating functional group. In one embodiment, each group -NRARB is independently W~ 00/34231 PCT/US99I29339 selected from the group consisting of -NHRA, -NHRARB,, and -NR~$. When not hydrogen, R", RB, and R~B, preferably comprise a reactive conjugating functional group.
The term "reactive conjugating functional group" is used herein to refer to reactive functional groups which facilitate conjugation, for example, with a biologically active molecule. Examples of such reactive conjugating functional groups include, but are not limited to, the following:
-OH
-SH
-NCO
--NCS
-NHRsus RA~KX
--RmKHgX
O
°C-H
O
-C-X
.~~-Rs O
°C-CH2X
O
-C-CRB=C(R8)2 O
-O-C-X
O
-C-OH
° ~,_ QRESTER
~~-O-~-Rs NRsue o n -c-o-c-NHRsu~
-~'N'N-Rsua -N-N-RsuB
O
-N
.
O
NRsus -C-QRsue O
.~S'ORALKX

O
O
I I
-S-X
II
O
O
-'~_"CRBy~RB)2 O

iH2 iH

In the above reactive conjugating functional groups, each X is independently F, Cl, Br, I, or other good leaving group; each R~'J" is independeni;ly an alkyl group, such as a linear or branched alkyl or cycloalkyl group having from 1 1:o about 20 carbon atams; each RS"s is independently H or an organic group, such as a linear or branched alkyl group, or a cycioalkyl group having from 1 to about 20 carbon atoms, an aryl group having from 6 to about 20 carbon atoms, or an alkaryl group having from 7 to about 30 carbon atoms; each RESTER is independently an organic group having from 1 to albout 20 carbon atoms, including, for example, primary, secondary, and tertiary alkyl and aryl groups having from 1 to about 20 carbon atarns; and, each R$ is independently a organic group, such as an organic group comprising 1 to 50 atoms selected from the group consisting of C, H, N, O, Si, P, and S.
In a preferred embodiment, the reactive conjugating functional group is an amino S group or a protected amino group. In one embodiment, th.e group -NR"R$
comprises an amino group, and has the structure:
-N/ \N-Hi In one embodiment, the group -NR"RB comprises a protected amino group, and has the structure:
/~ I!
- ~N-G-O-CH2 which is often conveniently abbreviated using "CBZ" to denote "carbobenzyloxy":
- ~N-Ge,z U
In one embodiment, the group -NR"RB comprises a hydrobromide salt of an amino group, and has the structure:
- ~NH.HBr U
In one embodiment, the group -NRARH comprises a haloacetyl group (where X
denotes Cl, Br, or I), and has the structure:
~--~ 0 -N/ \N- IC-CH2-X
In one embodiment, the group -NR"RB comprises an amino group, and has the structure:
-NH~CHZ~NFI2 ~n wherein n is a positive integer .from 1 to about 20, preferably from 1 to about 10, preferably from 1 to about 5. In one embodiment, the group -NR~R$ comprises a protected amino group, and has the structure:

i Hs -NH-CH2CH2-NH-C-(J-C-CH3 i which is often conveniently abbreviated using "BOC" to denote "tert-butoxycarbonyl":

In one embodiment, the group -NR"RB comprises an amino group, and has the structure:
-NH-f-CH2CH20-t-CH2CH2-NH2 ~n wherein n is a positive integer from 1 to about 20, :preferably from 1 to about 10, preferably from 1 to about 5.
Examples of valency platforms having the structure of Formula I are shown in Figures 2, 3, and 7. In Figure 2, the top structure has n=l and y'=I and the bottom structure has n=2 and y'=1. In Figure 3, the top structure l'~as n=1 and y'=2 and the bottom structure has n=2 and y'=2. In Figure 7, the structure has :n---4 and y'=2.
The number of I 5 terminal groups -NRaRB is given by "n*y'." When "n*y'" is 4, the structure may conveniently be referred to as a "tetrameric" structure. When "n*y'" is 8, the structure may conveniently be referred to as a "octameric" structure. When "n*y'" is I6, the structure may conveniently be referred to as a "hexadecameric" stn~cture.
Examples of compounds having the structure of Formula I where Z is -H include, but are not limited to, compounds 21, 24, 27a, 29, 32, and 38, described in the Examples below.
Examples of compounds having the structure of Formula I where Z is -C(=O)OR~~'~ include, but axe nat limited to, compounds 22, 25, 27, 30, 33, and described in the Examples below.

Examples of compounds having the structure of Formula I where Z is -NR"RB
include, but are not limited to, compounds 23, 23a, 26, 26a, 31, 31a, 34, 34a, 40, 41, 42, and 51, described in the Examples below.
Formula iI
In one embodiment, the present invention pertains to a valency platform having the structure of Formula II, as shown in Figure 1.
Formula ll R° J-~C-N G'-O-IC-!J G2-o-"Z
"~ '~ , [ R" ~ 2-)~ Y
2-y~
1~
In Formula II, n, R~, J, R", Ra, y', R~', G' , and Z acre as defined above for Formulae I. In Formula II, yz and GZ are as defined above for y' and G', respectively.
Examples of valency platforms having the structure of Formula II are shown in Figures 4 and 5. In Figure 4, the top structure has n=1, y'==2, and y2=1 and the bottom structure has n=i, y'=2, and yz=2. In Figure S, the structure has n=2, y'=2, and y'-=2. The number of terminal groups -NR~RB is given by "n*y'*y2." When "n*y'*y2" is 4, the structure may conveniently be referred to as a "tetrameric" structure. When "n*y'*y'-" is 8, the structure may conveniently be referred to as a "octamexic" structure. When ''n*y'*y2" is 16, the structure may conveniently be referred to as a "hex:adecameric"
structure.
Examples of compounds having the structure of Formula II where Z is -H
include, but are not limited to, compounds 35, 43a, and 49a, described in the Examples below.

Examples of compounds having the structure of Formula II where Z is -C{=O)ORc"'~ include, but are not limited to, compounds :3Sa, 43, and S0, described in the Examples below.
S Examples of compounds having the structure of Formula II where Z is -NR~RB
include, but are not limited to, compounds 14, 1 S, 20, ZOa, 28, 28a, 36, 36a, 44, 44a, and 4S, described in the Examples below.
Formula III
In one embodiment, the present invention pertains to a valency platform having the structure of Formula III, as shown in Figure 1.
Formula ill O O O
R~ J-CI-N G'-O-iC-N G2-O-IC-IN G3-O-Z
. ~ ~~ N ~ Y3 RN ~ ~ RN ~ 2_f~ 2_Ys ~ t 2_y~ Y
1 S In Formula III, n, R~, J, R", RB, y', y2, RN, G', Gz, and Z are as defined above for Formulae I and II. In Formula III, y3 and G~ are as defined above for y1 and G', respectively.
Examples of a valency platform having the structure of Formula III is shown in Figure 6. This structure has n=2, y'=2, y2=2, and y3=2. The number of terminal groups -NR~RB is given by "n*y'*y2*y3." When "n*y'*y2*y3" is 4, the structure may conveniently be referred to as a "tetrameric" structure. When "n*y'*yz*y3" is 8, the structure may conveniently be referred to as a "octameric" structure. When "n*y'*yz*y'" is 16, the structure may conveniently be referred to as a "hexadecameric" structure.

Formulae IV, V, and VI
In one embodiment, the present invention pertains to a valency platform having the structure of Formula IV, V, or VI, as shown in Figure $.
Formula 1V

R° J-'C-N-G' O-Z
Y~
Formula V

R° J-C-N-G' O-C-N-Gz O-Z
~N ~N
Y~
Formula VI
o o R~ J-C ~ G~ O-IC- I -G2 O-C~-N-G3 O-Z

Y~
In these formulae, n, R~, J, R~, RH, RN, and Z are as defined above for Formulae I
through III. Unlike the compounds of Formulae I through III, which may have branch points at nitrogen atoms, compounds of Formulae IV throul;h VI may have branch points at a G group, for example, at G', G2, or G3, and there may be one, two, three, or more branches, for example, y', y2, or y3 branches.
For Formulae IV through VII, G', GZ, and G3 are similar to G', Gz, and G3 for Formulae I through III. In a preferred embodiments, these l;roups are trivalent, tetravalent or higher. In one embodiment, G', G2, and G3 are selected from the group consisting of IH2-~ IH2.-~ IH2_...
""' i H ~ - i -CH3 ~ - i -CH2CH3 CH2- ~ CH2- ~ and cH2 Also, for Formulae IV through VI, y', y2, and y3 acre positive integers from 1 to about 10, more preferably from 1 to 5, more preferably from 1 to 4, more preferably from 1 to 3, more preferably from 1 to 2:
Examples of compounds having the structure of Formula IV where Z is -H
include, but are not limited to, compound 46, described in the Examples below.
Examples of compounds having the structure of Formula IV where Z is -C(=O)OR~'~ include, but are not limited to, compound 4~7, described in the Examples below.
Examples of compounds having the structure of Formula V where Z is -H include, but are not limited to, compound 47a, described in the Examples below.
Examples of compounds having the structure of Formula V where Z is -C(=O)OR~"'~ include, but are not limited to, compound 48, described in the Examples below.
Examples of compounds having the structure of Formula V where Z is -NR"RB
include, but are not limited to, compounds 48a, 48b, and 4~8c, described in the Examples below.
In general, the number of termini may be calculated.as the product of n, y', y2, y3, etc., as discussed above. In one embodiment, this product is 2 or more. In one embodiment, this product is more than 2. In one embodiment, this product is more than 3.
In one embodiment, this product is 4. In one embodiment, this product is 6. In one embodiment, this product is 8. In one embodiment, this product is 16. In one embodiment, this product is 32.
In some embodiments, the valency platform molecule may be described as "dendritic," owing to the presence of successive branch points. Dendritic valency platform molecules possess multiple termini, typically 4 or more termini. In one embodiment, the valency platform molecule is dendritic and has 4 termini, such as, for example, compounds 23a, 2&a, 31a, 34a, 42a, described in the examples below. In one embodiment, the valency platform molecule is dendritic and has 8 termini, such as, for example, compounds 1 S, 20a, 28a, 36a, 4S, 48c and S1, described in the examples below. In one embodiment, the valency platform molecule is dendritic and has 16 termini"
Note that ForrnuIae I through Vi are intended to encompass both "symmetric"
and "non-symmetric" valency platforms. In one embodiment, the valency platfor~rrr is I S symmetric. In one embodiment, the valency platform is non-symmetric. For example, each of the "n" groups which are pendant from the core group, RC, may be the same or may be independently different.
"Higher generation" valency platforms (e.g., 4th generation, Sth generation}
are also contemplated, which have corresponding formulae. For e~;ample, 4th generation valency platforms would have G4 and y4, 5th generation valency platforms would further have G~
and ys, and so on for successive generations. Also, "hybrid" valency platfor~rrrs are contemplated, which would include linkages of the sort found in Formulae I
through III as well as linkages of the sort found in Formulae IV through 'VI.

B. Preparation of Valency Platforms In one embodiment, the valency platforms of the present invention may be prepared from "core" compounds which comprise one or more (say, j°) hydroxy groups (i.e., -OH).
For example, the hydroxyl groups on the core are converted to active carbonate derivatives, such as activated carbonate esters (for example, apara-nitrophenylcarbonate ester) and subsequently reacted with a polyhydroxyamine compounds having j I hydroxy groups to provide a "first generation" carbamate with j' hydroxyl groups for each original hydroxyl group, for a total of j°*j' hydroxyl groups. The resulting hydroxy groups may then also be converted to activated carbonate derivatives, such as activated carbonate esters and subsequently reacted with a polyhydroxyamine compound. having j2 hydroxy groups to provide a "second generation" carbamate with j2 hydroxyl groups for each j' hydroxyl group, for a total of j°*j'*j2 hydroxyl groups. In this way, a dendritic structure may be constructed. The process can be terminated at any "generation" by treating the terminal activated carbonate derivatives, such as activated carbonate esters, with an appropriately functionalized compound (for example, an mono-protected diamine) to provide whatever functionality is desired at the termini.
In one embodiment, the valency platforms of the present invention may be prepared from a "segmental approach" in which "segments" are independently synthesized and subsequently attached to a "core" group In another embodiment, an alternative, more eff cie:nt "core propagation"
process has been developed in which a core group is modified in an iterative process to generate a dendritic structure. The core propagation approach involves fewer steps and is preferred over the segmental approach.
In another embodiment, the valency platforms of the present invention may be prepared using solid phase synthesis from a hydroxyl containing resin. Such an embodiment is illustrated in Figure 20. A hydroxyl group attached to a solid phase by a cleavable linker provides a way of building a dendrimeric scaffold using solid phase synthesis. The ability to prepare scaffolds on the solid phase can be particularly useful for the rapid synthesis of dendrimeric platforms with minimal purification. Also, solid phase dendrimeric platforms can be used to generate combinatorial Libraries of multivalent compounds.

In one preferred "core propagation" approach, the; synthesis typically begins with an alcohol containing "core compound." In principle, any hydroxyl-containing compound can be used. Examples of alcohol containing "care compounds" having one hydroxyl group {i.e., -OH) include, but are not limited to:
methanol, ethanol, CH3-CHz-OH
prapanol, CHswCHz-~CH2-OH
isopropanol, OH

methaxypalyethylene glycol, CH30 CHz-CHz-O H
n IS
Other examples of alcohol containing "core compounds" having one hydroxyl group (i.e., -OH) include, but are not limited to, mono-hydroxylamines, such as those described below, for which the amino group may be in a protected form, for example, using a BOC or CBZ protecting group.
Examples of alcohol containing "core compounds" having two hydroxyl groups (i.e., -OH) include, but are not limited to:
ethylene glycol, HO-CHz-CHz-OH
diethylene glycol (also referred to as DEG), HO-CHz-CHz-O-CHz-CHz-OH
triethylene glycol (also referred to as TEG), HO-CHz-CH2-O-CH2-CH2-O-CI-~2-CHz-OH

tetraethylene glycol, pentaethylene glycol, HO CHz-CH2-O H
hexaethylene glycol, polyethylene glycol {also referred to as PEG), where n is typically from 1 to about 20p, n I ,4-dihydroxymethylbenzene, HOCH2 ~ ~ CH20H
Other examples of alcohol containing "core compounds" having two hydroxyl groups (i.e., -OH) include, but are not limited to, primary or secondary amines having two I S hydroxyl groups, such as those described below. Again, the amino group may be in a protected form, for example, using a BOC or CBZ protecting group.
Examples of alcohol containing "core compounds" having three hydroxyl groups {i.e., -OH) include, but are not limited to:
phluoroglucinol (also known as I,3,5-trihydroxybenzene), OH
HO / OH

1,3,5-trihydroxymethylbenzene, HOCH2 ~ CH20H
1,3,5-trihydroxycyclohexane, OH
HO OH
Other examples of alcohol containing "core compounds" having three or more hydroxyl groups (i.e., -OH) include, but are not limited to, :primary or secondary amines having three hydroxyl groups, such as those described below. Again, the amino group may be in a protected form, for example, using a BOC or CBZ protecting group.
Examples of alcohol containing "core compounds" :having four hydroxyl groups (i.e., -OH) include, but are not limited to:
pentaerythritol, ~ H20H
HOCH2- i -CH20H

Further examples of alcohol containing "core compounds" include, but are not limited to, those which comprise a sulfhydryl group (i.e., -SH), which may be protected, for example, with a trityl protecting group (i. e., as -S-Tr, that is, -S-C(C6H5)3) or as a disulfide (i. e., as -S-SR). Examples of core groups which have a protected sulfhydryl group include, but are not limited to, the following:
Tr-S-CH2CH2-OH

i Hs where n is from 1 to about 200, preferably from 1 to about 20.
In addition, hydroxyl groups on solid phase synthesis resins can be used as core groups to provide dendrimeric carbamate residues on solid phase which can be used to boost the valence of the resin or cleaved off the resin. For example, a Wang resin of the following form may be used:
CH20~~ CH20H
In one embodiment, a hydroxy containing core groaap may be prepared from a corresponding carboxylic acid compound or halocarbonyl compound:
HN(CHZCH20H)2 pyridine or Et3N /CH2CH20H
R-COOH --a. R-COX ~~. R-CO-N
\GH2CH20H
Core compounds which possess amino or sulfl~ydryl groups, which may be protected or unprotected, may be used to covalently attach the resulting valency platform molecule to other molecules of interest, via the core group rather than via the termini, using conjugation methods such as those described herein.
In one step, the hydroxyl groups of the alcohol containing core group are converted to active carbonate derivatives. The active carbonate derivative in one embodiment has the formula:
O

O C
X

where X is a leaving group such as CI, irnidazole or thiolate.

The hydroxyl groups of the alcohol can be converted to active active carbonates by reaction of the hydroxyl groups of the alcohol containing core group with a phosgene equivalent. Phosgene equivalents with appropriate reactivity can be selected.
The phosgene equivalent has, for example, the structure X~(CO)XZ where X~ and Xz are both Leaving groups. X, and XZ each independently can be chosen from typical leaving groups in acylation chemistry such as alkoxide, thiolate, halide, quid imidazole. In one preferred embodiment, the phosgene equivalent is 4-nitrophenylchloroformate. In another embodiment, the phosgene equivalent is carbonyldiimida;aole. Other exemplary phosgene equivalents include phosgene, N,N'-succinimidylcarbonate, succinimidyl 2,2,2-trichloroethylcarbonate, bis-4-nitrophenylcaxbonate, triphosgene, 2,2,2-trichloroethyichloroformate, 4-nitrophenylchloroformate, phenylchioroformate, N-hydroxysuccinimidylchloroformate, trichloromethylchloroformate, ethylchlorothiolformate, di-(1-benzotriazolyl)carbonate, and 4-nitrophenylsuccinimidylcarbonate.
Thus, in one embodiment, to form an active carbonate derivative in the synthesis of the valency platform molecule, an alcohol is reacted with 'the phosgene equivalent to form the activated carbonate by displacing X, . X, is chloride in. one preferred embodiment. The active carbonate derivative is used to acylate an aminoalcohol on the nitrogen, forming the caxbamate bond, then the phosgene again is added to convert the hydroxyl group to another active carbonate derivative. An example of an active carbonate derivative is compound 39c shown in Figure 21.
In one embodiment, the active carbonate derivative; is a carbonate ester. The terms "carbonate" and "carbonate ester" are used herein in the conventional sense and relate to species which comprise the following structure:

-o-c-o-R' wherein R' denotes a carbonate group, such as an organic group having from 1 to 20 carbon atoms. The terms "activated carbonate" and "activated carbonate ester"
are used herein to refer to carbonates for which R' is an activating group, and for which the moiety -O-R' forms a good leaving group. A particularly preferred class of activated carbonate esters include, but are not limited to para-nitrophenyl carbonate ester compounds of the formula:
o _ p IC-O ~ ~ N02 Such "PNP" activated carbonate esters may readily be formed from the corresponding alcohol, R-OH by reaction with PNP chloro~formate in the presence of pyridine (CSHSN) in methylene chloride (CHZC12). ' O _ R-OH + CI-C-p--~~ ~ Npz pyridine, CH2CI2 O
--~"- R-O_C'p--(~ ~ N02 Examples of other activated carbonate groups include, but are not limited to, the following:

-o-c~
o O
-O-C_(~_N
p -o-c-o-cH2 In another step, the activated carbonate ester is converted to the corresponding carbamate. The above PNP activated carbonate esters are readily converted to the corresponding carbamates by reaction with an amine. The dlendritic structure may be extended by employing a primary or secondary amine having j' hydroxy groups.
In this way, each original hydroxy group, which led to an activated carbonate ester group, then leads to j' hydroxy groups.
Fox example, the PNP activated carbonate ester may be reacted with a primary or secondary dihydroxyamine. Examples of primary and secondary amines having two hydroxyl groups include, but are not limited to:
diethanolamine, , HN

bis(diethyleneglycol)amine (compound 7), (CW2CH20)2-H
HN
~(CH2CH20)2-H
bis(triethyleneglycol)amine, (CH2CH20)3-H
HN
~(CH2CH20)3-H
bis(tetraethyieneglycol)amine, (CH2CH20)4-H
HN
~(CH2CHz0)4-H
1 ~ bis(pentaethyleneglycol)amine, (CH2CH20)5-H
HN
~(CH2CHz0)5-H
bis(hexaethyleneglycol)amine (compound 4), (CH2CH2O)6-H
HN
~(CH2CH20)6-H
bis(polyethyleneglycol)amine (where n is from I to about 20), ~ (CH2CH20)"-H
HN
~(CH2CH20)"-H

diisopropanolamine, OH' /CH-CHz-CH3 HN
NCH- i Hz-CH3 OH
serinol (also known as 2-amino-1,3-propanediol), f H2 HO-CHz-CH-CHz-OH
2-amino-2-methyl-1,3-propanediol, ~ Hz HO-CHz- ~ H-CHz-OH

2-amino-2-ethyl-1,3-propanediol, i Hz HO-CHz-CH-CHz-OH

tris(hydroxymethyl)aminomethane, i H20H
HOCHz- ~ -NHz tris(hydroxyethyl)aminomethane, i H2CH20H
HOCH2CH2-L-NHz 1-amino-1-deoxysorbitol (also referred to as glucamine), NHz H OH
HO H
H OH
H OH

N-methyl-D-glucamine, H OH
HO H
H OH
H OH

In one step, the activated carbonate ester is converted to the corresponding carbamate using a monohydroxyamine to maintain vaiency from one generation to the next yet impart unique properties such as arm length, steric bulb;, solubility, or other physical properties. Examples of such monohydroxyamines include, but are not limited to:
3-pyrrolidinol, OH
NH
2-(hydroxyrnethyl)pyrrolidine, NH
3-hydroxypiperidine (also referred to as 3-piperidinol), off i NH
3-(hydroxymethyl)piperidine, NHJ
2-(hydroxymethyl)piperidine, NH~CH2-OH

WO 00/34231 PCTlUS99/29339 4-(2-hydroxyethyl)piperidine, NH
4-piperidinol, OH
J
NH
2,2,6,6,-tetramethyl-4-piperidinol, OH
CH3 ~CH3 mono-amino-oligoethylene glycol (where n is from 1 to about 10), HZN-r-CH2CH20~ H
~n mono-amino-polyethylene glycol (where n is frorr.~ 1 to about 200), H2N l CH2CH20-f--H
In one step, the activated carbonate ester is converted to the corresponding carbamate using a primary or secondary amine which acts as a "terminating"
amine. In one embodiment, a mono-protected diamine is employed. In a preferred embodiment, the I 5 terminating amine is a mono-CBZ protected piperazine, since this compound provides a convenient secondary amine handle for adding functionality by acylation with other reactive groups such as haloacetyl, maleimidoyl, etc. depending on what is desired at the N-terminus. For example, reaction with mono-CBZ-protected piperazine in the presence of triethylamine ((CH3CH2)3N) in methylene chlaxide (CHZC:l2) yields the CBZ-protected piperazine carbamate, which can then be converted to a haloacetyl group:

H-N N-CB;Z
O
_ II (CH3CH2)sN II
O-C O ~ ~ N02 ~'-O C- ~N-CBZ
II ~ o -O-C- UN-CBZ -----.s ~-O-C-N~N-C-CHZX
Ethylenediamine and other diamines can function ;similarly. Examples of preferred terminating amines include, but are not limited to those shown below, as well as mono-protected (e.g., mono-CBZ-protected) forms thereof piperazme, H-N N-H
ethylenediamine, propylenediamine, aikylenediamines (where n is an integer from 1 to about 20), n N,N'-dimethylethylenediamine, a,w-diaminopolyethyleneglycol (where n is an integer from 1 to about 200, preferably from 1 to about 20), n A particularly preferred terminating amines is mono-CBZ-protected piperazine:
O
H-N\ 'N-C-O-CH2 ~/
In principle any primary or secondary amine containing compound which contains a reactive conjugating group (such as those described above) or a biologically active molecule can be. used to terminate the dendrimer and provide the terminal functionality that is desired. For example, amino alcohols would provide terminal hydroxyl groups, amino aldehydes would provide terminal aldehyde groups, amino acids would provide terminal carboxylic acids, and aminothiols would provide terminal thiols. Methods for the introduction of other reactive conjugating functional groups, such as those described above, as terminating groups are well known to those of skill in the art.
C. Valenc Platform Con'ugates, Methods of Preparation, and Uses Thereof In one embodiment, valency platform molecules a~~e provided which act as scaffolds to which one yr more molecules may be covalently tethered to form a conjugate.
Thus, in another aspect, the present invention pertains to valency platform conjugates:
In one embodiment, the valency platform is covalently linked to one or more biologically active molecules, to form a conjugate. The team "biologically active molecule" is used herein to refer to molecules which have biological activity, preferably in vivo. In one embodiment, the biologically active molecule; is one which interacts specifically with receptor proteins.
In one embodiment, the valency platform is covale,ntly linked to one or more oligonucleotides, to form a conjugate. In one embodiment, the valency platform is covalently linked to one or more peptides, to form a conjul;ate. In one embodiment, the valency platform is covalently linked to one or more polypeptides, to form a conjugate. In one embodiment, the valency platform is covalently linked to one or more proteins, to form a conjugate. In one embodiment, the valency platform is covalently linked to one or more antibodies, to form a conjugate. In one embodiment, the valency platform is covalently linked to one or more saccharides, to form a conjugate. In one embodiment, the valency platform is covalently linked to one or more polysaccharides, to form a conjugate. In one embodiment, the valency platform is covalently linked to one or more epitopes, to form a conjugate. In one embodiment, the valency platform is covalently linked to one or more mimotopes, to form a conjugate. In one embodiment, the valency platform is covalently linked to one or more drugs, to form a conjugate.
In one embodiment, the biological molecule is first modified to possess a functionalized linker arm, to facilitate conjugation. An example of such a functionalized linker arm is a polyethylene glycol disulfide, such as, for example:
O S/S, CH3 n I -CH3 CHs One advantage of the valency platforms of the present invention is the ability to introduce enhanced affinity of the tethered biologically active molecules for their binding partners. Another advantage of the valency platforms of the present invention is the ability to facilitate crosslinking of multiple ligands, as is useful in B cell tolerance. Another advantage of the valency platforms of the invention is the ability to include functionality on the "core" that can be independently modified to enable the preparation of conjugates which can be tailored for specific purposes.
Conjugates of the valency piatfor~rn molecule and one or more biologically active molecules may be prepared using known chemical synthetic methods. As discussed above, the termini of the valency platform molecule (i. e., the R", R$, and/or R'°'B of the group -NR"RB, as discussed above) preferably comprise a reactive conjugating functional group, and this reactive functional group may be used to couple fhe valency platform to the desired biologically active molecule.

In one embodiment, the reactive haloacetyl group may be used to couple the valency platform to a biologically active molecule which possesses one or more reactive conjugating functional groups which are reactive towards the haloacetyl group, and which react to yield a covalent linkage.
S
For example, if the biologically active molecule is a protein which has one or more free amino groups (i.e., -NHZ), the two groups may be used to form the conjugate:
o vaiency platform-C-CH2X + H2N-protein C) II
valency platform-C;-CH2--NH-protein In another example, if the biologically active molecule is a protein which has one or more free thiol groups (i.e., -SH) or sulfide groups {i.e., -SR), the two groups may be used to form the conjugate:
o II
valency platform-C-CHzX + RS-protein C>
valency platform-C.-GH2--S protein In another embodiment, a terminal maleimidoyl group may be used to couple the valency platform to a biologically active molecule which possesses one or more reactive conjugating functional groups which are reactive towards i;he maleimidoyl group, and which react to yield a covalent linkage.
For example, if the biologically active molecule is a protein which has one or more free thiol groups (i.e., -SH) or sulfide groups (i.e., -SR), the two groups rnay be used to form the conjugate:

O
vaiency platform-N~ + RS-protein O~~~i' O
S-protein --~~ valency platform--N
O
D. Examples Several embodiments of the present invention are illustrated in the Examples below, which are offered by way of illustration and not by way of limitation.
Example 1 Examples of Synthesis of Amine Diols IO
A chemical scheme for the preparation of HEGA (bis-hexaethyleneglycolamine) is shown in Figure I 0. One hydroxy terminus of hexaethylene glycol is f rst converted to a tosyl group (compound 1 ), which is then converted to a bromo group (compound 2). The resulting compound is then reacted with tosylamide to yield tosylated bis-I S hexaethyleneglycolamine (compound 3). The tosyl group is then removed to yield the desired bis-hexaethyleneglycolamine (compound 4).
A chemical scheme for the preparation of DEGA (bis-diethyleneglycolamine) is also shown in Figure 10. Chlorodiethylene glycol (compound 5) is reacted with 20 aminodiethylene glycol (compound 6) to yield the desired bis-diethyleneglycolamine {compound 7).
Compound 1 Hexaethyleneglycol mono-tosylate 25 g (88.5 mmol) of hexaethyleneglycol was stirred at 0°C in 200 mL of CHZC12, and 14.3 mL of pyridine ( 177 mmol; 2 eq.) was added to the mixture followed by 17.4 g WO 00/34231 PCTlUS99/29339 (88.5 mmol) of tosylchloride. The reaction mixture was stirred at room temperature for 24 hours and partitioned between 400 ml of IN HCl and 200 ml of CHzCl2. The organic layer was dried over MgS04, filtered, and concentrated to provide 31 g of a light yellow oil.
Purification by silica gel chromatography (CHZClZ/MeOH) provided 15.32 g (40%) of 1 as S a light yellow oil:'H NMR (CDC13) 8 2.45 (s, 3H), 3.SS- ..75 (m, 22H), 4.1 S
(t, 2H), 7.35 (d, 2H), 7.80 (d, 2H); HRMS (FAB) calculated for C,~H33~O9S (M+H): 437.1845.
Found:
437.1834.
Compound 1 Hexaethyleneglycoi mono-tosyiate SO g of HEG (177 mmol) was dissolved in 300 ml of CHZCIz and 7.2 ml (8$ mmol) of pyridine was added at room temperature. 17.4 g (8$ mrnol) of tosylchloride was added to the mixture in four batches, each 2 hours apart. After the last addition, the mixture was 1 S stirred for 16 hours. The reaction mixture was concentrated, 1 S 0 mL of 0.1 M HCI was added, and the mixture was extracted twice with hexane to remove excess tosylchloride.
The aqueous layer was washed with three portions of ether to remove di-tosylate. This was carefully monitored by TLC to avoid any removal of mono-tosylate. The aqueous Iayer was then extracted with portions of CHzGl2 . The combined organic layers were washed with 0. I M HCI, dried over MgSOQ, filtered, and concentrated to give 23.6 g (31 %) of compound 1.
Compound 2 Hexaethyleneglycol mono-bromide Compound I (I 8 g, 41.3 mmoI) was dissolved in 12;0 mL of acetone and 10.8. g of Liar (124 mmol) was added. The mixture was stirred at 60~°C for 2 hours, the reaction mixture was allowed to cool to room temperature, and S00 mL of H20 was added.
The mixture was extracted with 2x 500 mL of CHzCI2. The corxibined organic layers were dried over MgS04, filtered, and concentrated to give 13.7 g (96%) of compound 2 as a light yellow oil: 'H NMR {CDCl3) b 3.50 (t, 2H), 3.60-3.75 (m, 20H), 3.83 (t, 2H);
HRMS
(FAB) calculated for C~ZH26BrO6 {M+H): 345.0913. Found: 345.0922.
Compound 3 N,N-his-hexethyleneglycol-tos;ylamide Compound 2 {3.5 g, 9.8 mmol) and 0.84 g (4.9 mmol) of tosylamide were dissolved in 35 mL of CH3CN. Potassium carbonate (1.63 g (11.8 mmol), which had been dried in the 100°C oven, was added, arid the mixture was refluxed for 18 hours under Nz.
The mixture was allowed to cool to room temperature, and 150 mL of HzO was added. The mixture was extracted with 3 X I50 mL of CHzCl2. The combined organic layers were washed with HBO, dried (MgS04), f ltered, and concentrated to give 3.3 g of a light yellow oil. Purification by silica gel chromatography (CHZCh /MeOH) provided 2.7 g (79%) of compound 3 as a light yellow oil:'H NMR (CDC13) b 2.45~ {s, 3H), 3.35 (t, 4H), 3.55-3.8 (m, 44H), 7.27 (d, 2H), 7.69, (d, 2H); HRMS (FAB) calculated for C3,HS,CsNO,4S
(M+Cs):
832.2554. Found: 832.2584.
Compound 4 N,N-bis-hexethyleneglycol-amine Compound 3, (2.74 g) was dissolved in 4 mL of dry THF and transferred to a three-neck flask equipped with a Dewar-condenser. This was sti~~ed at -78°C
as 100 mL of NH3 was condensed into the mixture. Approximately 1-2 g of Nfa was added to the mixture at -78°C in small portions until the dark blue color persisted. The cooling bath was removed, and the mixture was then stirred at reflux for 30 minutes. Cooling at -78°C was continued, and the reaction was carefully quenched with glacial acetic acid until all the blue color disappeared. The NH3 was allowed to evaporate, and the white solid was dried under vacuum to yield compound 4. This material was used as is in subsequent steps assuming a 100% yield.

Compound 7 DEGA {bis-diethyleneglycol~amine) Compound 7 was prepared according to an existing literature procedure as shown below (Bondunov et al., J. Org. Chem. I995, Vol. 60, pp. b097-b102). 33.8 g (32I mmol) of aminodiethyleneglycol (compound 6), 9.4 g ( 88.3 mmol) of Na2C03, 200 mL of toluene, and 10.0 g (80.3 mmol) of chlorotriethyleneglycol (compound 5), were refluxed with a Dean-Starke trap to remove water for 48 hours. The mixture was allowed to cool then filtered and concentrated. The resulting 45.8 g of material was vacuum distilled (bp 153-~ 158°C, 0.1 Torr) to yield 12.0 g {78%) of compound 7.
Example 2 Synthesis of Uctamer of HEGA/TEG Using Segmental Approach A chemical scheme for the preparation of an octamer of HEGA/TEG is shown in Figures 11 A and I 1 B. Compound. The bis-hexaethylene~;lycolamine {compound 4) was reacted with di-tert-butyldicarbonate to yield the N-BOC <;ompound (compound 8), which was then reacted withpara-nitrophenylchloroformate to yield the para-nitrophenylcarbonate compound (compound 9). Thepara-nitrophenylcarbonate (PNP) group was then converted to a carbamate group by reaction with mono-CBZ-protected piperazine, yielding compound 10. The BOC group was removed using trifluoroacetic acid to yield compound 1 I . Compounds 9 and 11 were then re;~cted together to form a"one-sided" dendritic compound (compound I2). Again, the BOC group was removed using trifluoroacetic acid to yield compound 13. Compound i 3 was then reacted with triethyleneglycol bis chlaroformate (from which the "core" is derived) to yield the "two-sided" dendritic compound (compound 14). The terminal CBZ-protected amino groups were then converted to the hydrobromide salt of amino group, and further reacted with bromoacetic anhydride to yield reactive bromaacetyl groups at each of the termini in compound 15.

Compound 8 N-BOC-N,N-bis-hexaethyleneglycol-amine Compound 4 (797 mg, I .46 mmol) was dissolved in 14 mL of H20, and the mixture was stirred at room temperature. To the mixture was added 465 mg (4.38 mmol) of Na,CO3. The pH was checked to make sure it was basic, and 319 mg (1.46- mmol) of di-tert-butyldicarbonate ((BOC)z0)was dissolved in 7 mL of dioxane and the resulting solution was added to the reaction mixture. The mixture was stirred at room temperature for 6 h and partitioned between 100 ml of H20 and 3 x 100 mL of CHZCIz. The combined organic layers were dried (MgS04), f ltered, and concentrated to give 605 mg (64%) of compound 8 as a light yellow oil: 'H NMR (CDCl3) 8 I .45 (s, 9H), 3.45 (m, 4H), 3.8-3.5 {m, 44H): MS (ESI) calculated for C29HssNaNO,4 (M+Na): 668. Found: 668.
Compound 9 Compound 8 (52 mg, 0.08 mmol) was dissolved in 3 mL of CHzCl2 and 97 mg (0.483 mrnol) of p-nitrophenylchloroformate was added to the mixture. The mixture was stirred at 0°C, 78 ~,L (0.966 mmol) of pyridine was added, and the mixture was then stirred at room temperature for 4 hours. The reaction mixture was cooled to 0°C, acidif ed with 1 N HCI, and partitioned between 10 mL of 1 N HCl and 3 x 10 mL of CHZCI,. The combined organic layers were dried {MgS04), and concentrated to give I 32 mg of an oil.
Purif cation was accomplished by silica gel chromatography (98 : 2 CHZCIz/MeOH) to give 57 mg (74.0%) of compound 9 as an oil: 'H NMR (CDC13) 8 1.49 (s, 9H), 3.43 (m, 4H), 3.52-3.77 (rn, 36H), 3.83 (m, 4H), 4.47 (m, 4H), 7.41 {d, 4H), 8.32 (d, 4H);
MS (ESI) calculated for C43HssNaN3022 (M+Na): 998. Found: 998.
Compound 10 Compound 9 {2.72 g, 2.79 mmoI) was dissolved in :l0 mL of CHZCh and the mixture was stirred at 0°C. To the mixture was added I.16 ml (8.36 mmol) of Et3N

followed by I .842g (8.36 mmol) of mono-CBZ-piperazine dissolved in 10 mL of CHZC12.
The mixture was stirred at room temperature for I 8 hour,;, cooled to 0°C, and acidif ed with 1 N HCI. The mixture was partitioned between I50 mL of I N HCI and 3 x 150 mL
of CH,CIz. The combined organic layers were washed with :saturated NaHCO~
solution, dried (MgS04) and concentrated to give 3.64 g of a yellow oil. Purification by silica geI
chromatography (97/3 CHzCI2JMeOH) gave 3.1 g (98%) of compound _10 as a light yellow oil: 'H NMR (CDCI3) 8 1.45 (s, 9H), 3.40-3.55 (m, 12H), 3.55-3.68 (m, 36H}, 3.71 (m, 4H), 4.37 {m, 4H), 5.17 (s, 4H), 7.35 {brd s, lOH); MS (ESI) calculated for CSSHB,NaN502o (M+Na): 1060. Found: 1060.
Compound 11 Compound I O {3.54 g, 3. I i mmol) was dissolved in 15 mL of CH~CI, and I5 mL
of trifluoroacetic acid (TFA) was added to the mixture. The nnixture was stirred at room temperature for 4 hours and concentrated. The residue was re-dissolved in I O
mL of CHzCIz and neutralized by shaking with a saturated solution of Na)EiC03 at 0°C. The mixture was then partitioned between 100 mL of saturated NaHC03 solution and 4 x 100 mL of CHZCIz.
The combined organic layers were dried (MgS04), f ltered, and concentrated to give 3.16 g of compound 11 {98%) as a yellow oil: 'H NMR {CDCl3) C~ 2.88 (t, 4H), 3.50 {brd s, 16H), 3.56-3.69 (m, 36H), 3.7I (m, 4H), 4.28. (m, 4H}, 5.15 (s, 4H), 7.38 (brd s, l OH); MS (ESI) calculated for CSOHg°N50'$ (M+H): 1037. Found: 1038.
Compound 12 Compound 9 (647 mg, 0.663 mmol} and 2.065 g ( / .989 mmol) of compound _1 I
were dissolved in 3 mL of CHZC12, and 462 ~cL (3.315 mmol) of Et~N and 40 mg (0.331 mmol) of DMAP (4-dimethylaminopyridine) was added to the mixture. The reaction mixture was stirred at room temperature overnight and cooled to 0°C. To the mixture was added 5 mL of H20, and the mixture was acidified with I N HCl and partitioned between 50 mL of H,O and 3 x 50 mL of CH~CIZ. The combined organic layers were dried {MgSO~}
so and concentrated to give 2.77 g (72.1 %) of a yellow oil. Purification by silica gel chromatography (CHZCI2/MeOH) gave 1.307 g (72%) of compound 12 as a yellow oil: 'H
NMR -(CDCl3) 8 1.46 (s, 9H), 3.49 (brd s, 32H), 3.52-3.67 (m, 92H), 3.69 (m, 8H), 4.22 (m, 12H); 5.15 (s, 8H), 7.3 S (brd s, 20H).
Compound 13 Compound 12 ( 1.3 g, 0.47 mmol) of the starting material was dissolved in i 0 mL of CHZCh and 10 mL of TFA (trifluoroacetic acid) was added. The mixture was stirred at room temperature for 4 hours, concentrated, and re-dissolved in 10 mL of CHZC12. The mixture was neutralized shaking with a saturated solution of NaHC03 at 0°C. The mixture was partitioned between 25 mL of saturated NaHC03 solution and 4 x 2S mL of CH~C12.
The combined organic layers were dried (MgS04) and concentrated to give 1.23 g (98%) of compound 13 as a yellow oil: 'H NMR (CDCl3) 8 3.48 (brd s, 32H), 3.53-3.67 {m, 92H), 3.71 (m, 8H), 4.22 (m, I2H), 5.15 (s, 8H), 7.38 (brd s, 20Ft).
Compound 14 Compound 13 (600 mg, 0.224 mmol) was dissolved in I :5 mL of CHZC12 and the mixture was stirred at 0°C. To the mixture was added 65 pL {0.373 mmol) of D1PEA
followed by the slow addition of a solution of 20.5 mg (0.075 mmol) of triethyleneglycol bis-chloroformate dissolved in 0.5 mL of CHZCIZ. After 3 hours the reaction mixture was cooled to 0°C and acidified with 1 N HCI. The mixture was partitioned between 25 ml of 1 N HCl and 2 x 25 ml of CHZC12. The combined organic layers were dried (MgS04) and concentrated to give 566 mg of alight yellow oil. Purif cati~on by silica gel chromatography (95/5 CHZCI2/MeOH) gave 14S mg of compound I4 (35%} as a light yellow oil: 'H
NMR
(CDCl3) 8 3.51 (brd s, 64H}, 3.54-3.77 (m, 272H), 4.23 (m, 28H), 5.17 (s, I6H}, 7.36 (brd s, 40H); MS (ESl) calculated for C260H421N22~)06 {M+H): 5549. Found: 5549.

Compound 15 Compound 14 (143 mg, 0.026 mmol) was treated with 3 mL of 30% HBr/AcOH far 30 min. The resulting HBr salt was precipitated with ether. The solids were collected by S centrifugation and washed three times with ether. The re;>ulting HBr salt was dried in the desiccator overnight and dissolved in 1.2 ml of H,O. The mixture was stirred at 0°C, and 97 mg (1.16 mmol) of sodium bicarbonate was added. A solution of 107 mg (0.412 mmol) of bromoacetic anhydride in I .2 mL of dioxane was added, the mixture was stirred at 0°C
for I S-20 min. To the mixture was added 10 mL of HZO, and the mixture was slowly acidified with 1 M H~S04 to a pH of 4. The aqueous layer was extracted with 2 x 10 mL of EtOAc which was discarded. The aqueous layer was then extracted with 6 x 10 mL
of 8/2 CHZCi,/MeOH. The combined organic layers were dried (:MgS04), filtered and concentrated to give I 17 mg of an oil. Preparative HPLC (C18, gradient, 3S-SS% B, A =
0.1 % TFA/H,O and B = 0. I % TFAICH,CN) to give 27 ml; (I 9%) of compound _1 S
as a IS colorless oil: 'H NMR (CDCl3) 3.46-3.75 (m, 336H), 3.90 (m, 16H}, 4.21-4.33 (m, 28H);
MS (ESI) calculated for Cz,2H38,Br$N220~$ (M+H): S43S. hound: 5448.
Example 3 Synthesis of Octamer of DEGA/TEG Using Segmental Approach A chemical scheme for the preparation of an octamer of DEGA/TEG is shown in Figures 12A and 12B. The bis-diethyleneglycolamine (compound _7) was reacted with di-tert-butyldicarbonate to yield the N-BOC compound {compound _16}, which was then reacted with para-nitrophenylchloroformate to yield the para-nitrophenylcarbonate 2S compound (compound I 7}. The para-nitrophenylcarbonate; (PNP) group was then converted to a carbamate group by reaction with mono-CB.Z-protected piperazine, yielding compound I 8. The BOC group was removed using trifluoroacetic acid to yield compound 18a. Compounds 17 and I 8a were then reacted together to form a "one-sided"
dendritic compound (compound 19}. Again, the BOC group was removed using-trifluoroacetic acid to yield compound 19a. Compound 19a was then reacted with triethyleneglycol bis chloroformate (from which the "core" is derived) to yield the "two-sided"
dendritic W~ 00/34231 PCT/US99129339 compound (compound 20). The terminal CBZ-protected amino groups were then converted to the hydrobromide salt of amino group, and further reacted with bromoacetic anhydride to yield reactive bromoacetyl groups at each of the termini in compound 20a.
Compound 16 N-BOC-N,N-bis-diethylenegly~:ol-amine To a solution of 600 mg ( 3.10 mmol) of bis-diethyleneglycolamine (compound in 9.9 mL of 10% aqueous Na2C03 was added slowly a solution of 678 mg (3.10 mmol) of di-tert-butyldicarbonate in S mL of dioxane. The mixture was stirred at roam temperature for S hours, and 2S mL of water was added. The mixture was shaken with Et20, the Et20 layer was discarded, and the mixture was extracted with three 2S mL portions of CH~CI2.
The CHZC12 extracts were combined, dried {MgS04), filtered and concentrated to give 717 mg (79%) of compound 16 as a viscous oiI: 'H NMR (CD~Cl3) cS 1.48 (s, 9H}, 3.45 (brd s, 1 S 4H), 3.60 {t, 4H}, 3.65 (brd s, 4H), 3.69 (brd s, 4H).
Compound 17 To a solution of 200 mg (0.68 mmol) of compound 16 and 822 mg g (4.08 mmol) of 4-nitrophenyichloroformate in 30 mL of CHZCIz was added 0.66 mL {8.16 mmol) of pyridine at 0°C. The mixture was stirred at room temperature for 1.S
hours then cooled back to 0°C, and the mixture was acidified with 1 N HCl and partitioned between SO mL of 1 N HCl and three SO mL portions of CHzCl2. The combined CHZC12 extracts were dried (MgS04), filtered and concentrated to give 1.21 g of yellow oil. The mixture was partially purified by silica gel chromatography (CHZC12/MeOH) to ;give S8I mg of partially purified compound 17 which still contained 4-nitrophenol: MS (ESl) calculated for CZ~Ha~NaN3O,4 (M+Na): 646. Found: 646. This material was used directly in the next step.

Compound I8 To a solution of 42I mg of partially purified compound 17 (0.68 mmol theoretical) and 282 ~,L (2.02 mmol) of Et3N in 4 mL of CHzCl2 at 0°C was added a solution of 446 mg (2.02 mmol) of mono-CBZ-piperazine in 4 mL of CHZC12. The mixture was stirred at room temperature for I.S hours, cooled back to 0°C, acidified with 1 N HCI, and partitioned between 50 mL of I N HCl and 3. X 50 mL of CHZCIz. Th.e combined CHzCIz layers were washed with saturated NaHC03 solution, dried (MgS04), filtered, and concentrated to give 500 mg of viscous residue. Purification by silica gel chromatography (CHZCh/MeOH) gave 265 mg (50%) of compound 18 as a viscous oil: 'H NMR (CDCl3) 8 I .45 (s, 9H), 3.40-3.70 (m, 28H), 4.28 (t, 4H), S.I6 (s, 4H), 7.37 (brd s, IOH); MS (ESI) calculated for C39HSSNaN5~t2 {M+Na): 808. Found: 809.
Compound I9 IS
Compound 18 (77 mg, 0.098 mmol) was dissolved :in I .5 mL of CHZCIZ and I .5 mL
of TFA was added. The mixture was stirred for 6 hours and concentrated. The residue was dissolved in 10 mL of CH2Clz and the resulting solution wa.s stirred at 0°C while I5 mL of saturated NaHC03 solution was added. 'The aqueous layer was extracted with 4 X
10 mL, of CH,Ch, and the combined organic layers were dried (M~;S04), filtered, and concentrated to give 62 mg (92%) of free amine, compound 18a: 'H NMIE~ (CDC13) 8 2.90 (t, 4H), 3.46 (brd s, 16H), 3.66 (m, 8H), 4.25 (t, 4H), 5.16 (s, 4H), 7.36 (brd s, I0H). To a solution of compound 17 in CH,CIz is added the free amine, compound I8a (3 eq.) and pyridine. The mixture is stirred at room temperature until the reaction appears done by TLC.
The product is isolated by extractive workup and purification by silica ge;l chromatography to give compound 19.

Compound 20 Compound 19 is dissolved in 1/l CHZCIz/TFA, and stirred at room temperature for 1 hour. The mixture is concentrated under vacuum to provide an amine intermediate, compound 19a. Two equivalents of the intermediate amine is reacted with triethyleneglycol bis-chloroformate in CHzCIz and pyridine. The product is isolated by extractive workup and purif cation by silica gel chromatography to give compound 20.
Compound 20a In a process similar to that described above for compound 15, compound 20 is treated with 30% HBr/AcOH for 30 min. The resulting HBr salt is precipitated with ether.
The solids are collected by centrifugation and washed with ether. The resulting HBr salt is dried in the desiccator overnight and dissolved in HzO. T:he mixture was stirred at 0°C and sodium bicarbonate added. A solution of bromoacetic anhydride in dioxane is added, and the mixture stirred at 0°C for 15-20 min. To the mixture is added H20, and the mixture is slowly acidified with 1 M HZS04 to a pH of 4. The aqueous layer is extracted with EtOAc which was discarded. The aqueous layer is then extracted with $/2 CHZC12/MeOH.
The combined organic layers are dried (MgS04), filtered and concentrated to give compound 20a.
Example 4 Synthesis of Tetramer of DEGA/TEG Using Core Propagation Approach A chemical scheme for the preparation of an tetramer of DEGA/TEG is shown in Figure 13. The bis-diethyleneglycolamine (compound 7) was reacted triethyleneglycol bis chloroformate (from which the "core" 'is derived) to yield the tetrahydroxy compound, compound 21. Compound 21 was then reacted with para-nitrophenylchioroformate to yield the tetrapara-nitrophenylcarbonate compound (com7pound 22). The para-nitrophenylcarbonate (PNP) group was then converted to a carbarnate group by reaction with mono-CBZ-protected piperazine, yielding compound 23. The terminal CBZ-protected amino groups were then converted to the hydrobromide :;alt of amino group, and further reacted with bramoacetic anhydride to yield reactive bromoacetyl groups at each of the termini in compound 23a.
S Corapound 21 To a solution of I.94 g (10.0 mmol) of compound 7 and 1.75 mL (1.30 g, 10.0 mmol) of EtjN at 0°C a solution of 980 ~,L (1.31 g, 4.78 nnmol} of triethyleneglycol bis-chlorofonnate in 3S mL of CHzCIz. The mixture was stirred for 3 hours at room temperature and concentrated to give 4.84 g of crude compound 21 which was used as is in the next step: 'H NMR (CDCl3) 8 3. I 0 (m, 4H}, 3.45-3.78 (m, 32H), 4.24 (m, 4H).
Compound 22 I S Pyridine (9.3 mL, 114.7 mmol) was added to a stiwed solution of 4.84 g of crude compound 21 (4.78 mmol theoretical) and 7.71 g (38.24 mmol) of 4-nitrophenylchlorofonnate at 0°C, and the mixture was stirred for 4 hours at room temperature. The mixture was cooled to 0°C and acidified with I N HCI.
The mixture was partitioned between 2S0 mL of 1 N HCl and 2 X 250 mL of CHZCIZ. The organic layers were combined, dried (MgS04), filtered and concentrated to give 9.81 g of crude product.
Purification by silica gel chromatography (CHZC12/MeOH) gave 4.40 g (74%) of compound 22 as a sticky viscous oil: 'H NMR (CDCl3) 8 3.56 (m, 8H), 3.61-3.72 (m, 16H), 3.76 (m, 8H), 4.23 (t, 4H), 4.44 (t, 8H), 7.40 (d, 8H), 8.2$, (d, 8H); HRMS (FAB) calculated for C52H60CSN~O30 (M+Cs}: 1381.2408. Found: 1381.2476.

Compound 23 A solution of I06 mg (0.48 mrnol) of mono-CBZ-piperazine in O.S mL of CHzClz was added to a stirred solution of 100 mg (0.08 mmol) of compound _22 and 67 p.L (0.48 mmol) of Et3N at 0°C. The mixture was stirred for 18 hours at room temperature, cooled to 0°C, and acidified with 1 N HCI. The mixture was partitiioned between S
mL of 1 N HCl and 3 X S mL of CHZCI2. The organic layers were combined, washed with saturated NaHC03 solution, dried (MgS04), filtered, and concentrated to give 119 mg of yellow oil.
Purification by silica gel chromatography (CHZCl2/MeOH) gave 81 mg {64%) of compound S 23 as a viscous oil: 'H NMR (CDC13) S 3.48 (brd s, 40H), 3.52-3.74 (m, 24H), 4.24 (t, 12H), 5.14 (s, 8H), 7.35 (brd s, 20H); HRMS (FAB) calculated for C,bH,°4CsN,°026 (M+Cs): 1705.6178. Found: 1705.6269.
Compound 23a In a process similar to that described above for compound 1 S, compound 23 is treated with 30% HBrIAcOH for 30 min. The resulting HBr salt is precipitated with ether.
The solids are collected by centrifugation and washed with ether. The resulting HBr salt is dried in the desiccator overnight and dissolved in HZO. The mixture was stirred at 0°C and 1 S sodium bicarbonate added. A solution of bromoacetic anlhydride in dioxane is added, and the mixture stirred at 0°C for 1 S-20 min. To the mixture :is added H20, and the mixture is slowly acidified with 1 M HzS04 to a pH of 4. The aqueous layer is extracted with EtOAc which was discarded. The aqueous layer is then extracted with 8/2 CHzCI2/MeOH.
The combined organic layers are dried {MgS04), filtered and concentrated to give compound, 23a.
Example 5 Synthesis of Tetramer of DEGA/PTH Using Core Propagation Approach 2S A chemical scheme for the preparation of an tetranner of DEGA/PTH is shown in Figure 14A. The bis-diethyleneglycolamine (compound i') was reacted with terephthaloyl chloride (from which the "core" is derived) to yield the tetTahydroxy compound, compound 24. Compound 24 was then reacted withpara-nitrophenylchloroformate to yield the tetra para-nitrophenylcarbonate compound (compound 2S). The para-nitrophenylcarbonate (PNP) group was then converted to a carbamate group by reaction with mono-CBZ-protected piperazine, yielding compound 26. The terminal CBZ-protected amino groups were then converted to the hydrobromide salt of amino group, and further reacted with bromoacetic anhydride to yield reactive bromoacetyl groups at each of the termini in compound 26a.
Compound 24 A solution of 300 mg (1.48 mmol) of terephthaloyl chloride in 9 mL of CH2C12 was slowly added to a 0°C solution of 600 mg (3.10 mmol} of 7 and 540 ~,L
(3.I O mmol} of diisopropylethylamine in 12 mL of CH2C12, and the mixture was stirred under nitrogen I 0 atmosphere for 3 hours at room temperature. The mixture was concentrated under vacuum to give I .53 g of a crude mixture which contained 24.
Compound 25 15 The 1.53 g of crude 24 and 2.38 g {I I .8I mmol) of 4-nitrophenylchloroformate were dissolved in 30 rnL of pyridine, and the resulting solution was stirred at 0°C while 1.91 mL (23.62 mmol) of pyridine was added. The mixture was stirred at room temperature for 4 hours, cooled to 0°C; and acidif ed with I N HCI. The mixture was partitioned between 75 mL of 1 N HCl and 2 X 75 mL of CHzCIz. The organic layers were 20 combined, washed with saturated NaHC03 solution, dried (MgS04), filtered, and concentrated to give 2.75 g of an oil. Purification by silica gel chromatography (CHzCl2/MeOH) gave 1.33 g (76%) of 25 as a viscous oil: 'H NMR (CDCl3) ~ 3.52 (brd s, 8H), 3.65 {brd s, 4H), 3.81 (brd s, I2H), 4.41 (m, 8H), 7.38 (m, 8H), 7.47 (s, 4H), 8.27 {m, 8H); HRMS {FAB) calculated for CSZH53N6o26 (M+H): 1 I 77.3010. Found: I
177.3062.
Compound 26 A solution of 113 mg (0.51 mmol) of mono-CBZ-piperazine in 0.5 mL of CHZCIz was added to a stirred solution of 100 mg (0.085 mmol) of compound _25 and 71 pL (0.51 mmol) of Et3N at 0°C. The mixture was stirred for 18 hours at room temperature, cooled to 0°C, and acidified with 1 N HCl. The mixture was partitioned between 5 mL of 1 N HCI

WO OoI3423I PCT/US99129339 and 3 X 5 mL of CHZCIZ. The organic layers were combined, washed with saturated NaHC03 solution, dried (MgS04), f ltered, and concentrated to give i 25 mg of yellow oil.
Purification by silica gel chromatography (CHZC12/MeOH) gave 59 mg (46%) of 26 as a viscous oil: 'H NMR (CDC13) 8 3.45 (brd s, 40H), 3.55 (m, 4H), 3.72 (m, 4H), 3.78 (s, 8H), 4.24 (m, 8H), S.I3 (s, 8H), 7.34 (brd s, 20H), 7.42 (s, 4H); HRMS {FAB) calculated for C,6H96CsN,flO~ (M+Cs): 1633.5755. Found: 1633.5846.
Compound 26a Tn a process similar to that described above for compound 15, compound 26 is treated with 30% HBr/AcOH for 30 min. The resulting FEBr salt is precipitated with ether.
The solids are collected by centrifugation and washed with ether. The resulting HBr salt is dried in the desiccator overnight and dissolved in HZO. The mixture was stirred at 0°C and sodium bicarbonate added. A solution of bromoacetic anhydride in dioxane is added, and the mixture stirred at 0°C for 1 S-20 min. To the mixture its added H20, and the mixture is slowly acidified with 1 M HzSOQ to a pH of 4. The aqueous layer is extracted with EtOAc which was discarded. The aqueous layer is then extracted with 8/2 CHzCIz/MeOH.
The combined organic layers are dried (MgSOd), filtered and concentrated to give compound 26a.
Example 6 ~nthesis of Octamer of DEGAJPTH, Using Core Propagation Approach A chemical scheme for the preparation of an octarr.~er of DEGA/PTH is shown in Figure 14B. The bis-diethyleneglycolamine {compound 7;) was reacted with the tetra para-nitrophenylcarbonate compound (compound 25) to yield tlae octahydroxy compound, compound 27a. Compound 27a was then reacted withpara-nitrophenylchloroformate to yield the octapara-nitrophenylcarbonate compound (compound 27). The para-nitrophenylcarbonate (PNP) group was then converted to a. ca.rbamate group by reaction with mono-CBZ-protected piperazine, yielding compound 28. The terminal CBZ-protected ammo groups were then converted to the hydrobromide salit of amino group, and further reacted with bromoacetic anhydride to yield reactive bromoacetyl groups at each of the termini in compound 28a.
Compound 27a A solution of 98 mg (0.51 mmol) of compound 7 iin 0.5 mL of CH2C12 was added to a stirred solution of 100 mg (0.085 mmol) of compound 25 and 71 ~.L (0.51 mmol) of Et3N
at 0°C, and the mixture was stirred for 18 hours. The mixture was concentrated to give 250 mg of crude product, compound 27a.
IO
Compound 27 Crude compound 27a (250 mg) was dissolved in 4 mL of CHZC12. The mixture was cooled to 0°C, and 275 mg (1.36 mrnol) of 4-nitrophenylclllaroformate was added followed I S by 220 p.L (2.74 mmol) of pyridine. The mixture was stirred at room temperature for 7 hours, cooled to 0°C, and acidified with I N HCI. The mixture was partitioned between 5 mL of 1 N HCl and 2 X 15 mL of CHZClz. The organic layers were combined, washed with saturated NaHCO~ solution, dried (MgS04), filtered, and concentrated to give 393 mg of an oiI. Purification by silica geI chromatography (CHZCIZ/MeOH) gave 123 mg (53%) of 20 compound 27 as a viscous oil: 'H NMR (CDCl3) 8 3.63-3.136 (m, 72H}, 4.46 {t, 24H), 7.26 (s, 4H), 7.35 (m, 16H), 8.24 (m, 16H}.
Compound 28 25 A solution of 6 eq. of mono-CBZ-piperazine in CHZC12 is added to a stirred solution of compound 27 and 6 eq. of Et3N at 0°C. The mixture is shirred for I8 hours at room temperature, cooled to 0°C, and acidified with 1 N HCI. The mixture is partitioned between I N HC1 and CHZCIz. The organic layers are combined, washed with saturated NaHC03 solution, dried (MgS04), filtered, and concentrated to give crude product which 30 can be purified by silica gel chromatography to give compo~.md 28.

Compound 28a In a process similar to that described above for compound 15, compound 28 is treated with 30% HBr/AcOH fox 30 min. The resulting HBr salt is precipitated with ether.
The solids are collected by centrifugation and washed witlh ether. The resulting HBr salt is dried in the desiccator overnight and dissolved in HzO. The mixture was stirred at 0°C and sodium bicarbonate added. A solution of bromoacetic anhydride in dioxane is added, and the mixture stirred at 0°C for 15-20 min. To the mixture is added H20, and the mixture is slowly acidified with 1 M H~S04 to a pH of 4. The aqueous layer is extracted with EtOAc which was discarded. The aqueous layer is then extracted 'with 8/2 CHZCIz/MeOH. The combined organic layers are dried (MgS04), filtered and concentrated to give compound 28a.
Example 7 Snthesis of Tetramer of HEGA/TEG Using Core Prop~a~ation Approach A chemical scheme for the preparation of an tetram~er of HEGA/TEG is shown in Figure i 5. The bis-hexaethyleneglycolamine (compound ~~) was reacted triethyleneglycol bis chloroformate (from which the "core" is derived) to yield the tetrahydroxy compound, compound 29. Compound 29 was then reacted withpara-nitrophenylchloroformate to yield the tetrapara-nitrophenylcarbonate compound (compound 30}. The para-nitrophenylcarbonate (PNP) group was then converted to a carbamate group by reaction with mono-CBZ-protected piperazine, yielding compound 31. The terminal CBZ-protected amino groups were then converted to the hydrobrornide salt of amino group, and further reacted with bromoacetic anhydride to yield reactive bromoacetyl groups at each of the termini in compound 31 a.

Compound 29 To a solution of 2. I eq. of compound 4 and 2.1 eq. of Et3N at 0°C is added a solution of 1 eq. of triethyleneglycol bis-chloroformate in CHzCIz. The mixture is stirred at room temperature until complete by TLC and concentrated to give crude compound _29 which is used as is in the next step.
Compound 30 Pyridine (12 eq.) is added to a stirred solution of cmde compound _29 and 6 eq. of 4-nitrophenylchloroformate at 0°C, and the mixture is stirred at room temperature until the reaction is complete as evidenced by TLC. The mixture is cooled to 0°C, and acidified with 1 N HCI. The mixture is partitioned between 1 N HC'i and CHzCIz. The organic layers are combined, dried (MgS04), filtered and concentrated to give crude product.
Compound 30 is purified by silica geI chromatography.
Compound 3I
A solution of 6 eq. of mono-CBZ-piperazine in CH;zCI2 is added to a stirred solution of compound 30 and 6 eq. of Et3N at 0°C. The mixture is stirred for at room temperature until the reaction is complete as evidenced by TLC, cooled to 0°C, and acidified with 1 N
HCI. The mixture is partitioned between 1 N HCI and CHZCIz. The organic layers are combined, washed with saturated NaHC03 solution, dried (MgS04), filtered, and concentrated to give crude compound 31 which is purified by silica gel chromatography.
Compound 31a In a process similar to that described above for compound _i 5, compound _31 is treated with 30% HBr/AcOH for 30 min. The resulting HB:r salt is precipitated with ether.
The solids are collected by centrifugation and washed with ether. The resulting HBr salt is dried in the desiccator overnight and dissolved in HzO. The mixture was stirred at 0°C and sodium bicarbonate added. A solution of bromoacetic anhydride in dioxane is added, and the mixture stirred at 0°C for 15-20 min. To the mixture its added H20, and the mixture is slowly acidified with 1 M HzS04 to a pH of 4. The aqueous layer is extracted with EtOAc which was discarded. The aqueous layer is then extracted with 8/2 CHZC12/MeOH.
The combined organic layers are dried (MgS04), filtered and concentrated to give compound 31 a.
Example 8 Synthesis of Tetramer of DEA/PTH Using Core Propagation Approach A chemical scheme for the preparation of an tetramer of DEGA/PTH is shown in Figure 16A. Diethanolamine was reacted with terephthaloyl chloride (from which the "core" is derived} to yield the tetrahydroxy compound, compound 32. Compound 32 was then reacted with para-nitrophenylchloroformate to yield the tetra para-nitrophenyicarbonate compound (compound 33). Thepara-nitrophenylcarbonate (PNP) group was then converted to a carbamate group by reaction with mono-CBZ-protected piperazine, yielding compound 34. The terminal CBZ-protected amino groups were then converted to the hydrobromide salt of amino group, and further reacted with bromoacetic anhydride to yield reactive bromoacetyl groups at each of the termini in compound 34a.
Compound 32 A solution of 2.0 g (9.85 mmol) of terephthaloyl chloride in 25 mL of THF was added slowly to a 0°C solution of 2.17 g (20.7 mmol) of di.ethanolamine and 3.6 mL (20.7 mmol} of diisopropylethylamine in 50 mL of THF. The mixture was stirred at room temperature for 3 hours and concentrated under vacuum to give 6.7 g of crude compound 32. A small amount was purified for characterization purposes by preparative HPLC (1"
C 18 column, gradient 0-15% B, A = 0.1 % TFA/H20 and E~ = 0.1 % TFA/CH;CN): 'H
NMR
(D20) 8 3.52 (m, 4H}, 3.59 (m, 4H), 3.72 {m, 4H}, 3.89 (m, 4H), ?.51 (s, 4H);
MS (EST) calculated for C16H25N2~6 (M+H): 341. Found: 341.

Compound 33 Pyridine (11.4 mL, 14I.2 mmol) was slowly added to a stirred solution of 6.01 g (8.8 mmol thearetical) of crude compound 32 and 14.2 g (70.6 mmol) of 4-nitrophenylchloroformate in 88 mL of THF. The mixture was stirred at room temperature for I 8 hours and acidified with 1 N HCI. The mixture wars partitioned between 300 mL of I N HCi and 2 X 300 mL of CH~CI2. The combined organic layers were washed with saturated NaHC03 solution, dried (MgS04), filtered, and concentrated to give 14.0 g of sticky orange oil. Purification by silica gel chromatography (CH,C12/MeOH) provided 3.34 g (38%) of compound 33 as a crystalline solid: mp 77-85°C; 'H NMR
(CDCl3) b 3.76 (brd, 4H), 4.OI (brd, 4H), 4.38 (brd, 4H), 4.64 (brd, 4H), 7.36 (brd, 8H), 7.53 (s, 4H), 8.28 (m, 8H);'3C NMR (CDC13) $ 45.0, 48.5, 65.9, 66.6, 12I.8, 125.0, I25.4, 126.1, 127.2, 137.1, 145.6, 152.4, 155.2, 171.9; HRMS (FAB) calculated for C,,4H36CsN6O2z (M+Cs):
1133.0937. Found: 1133.0988.
Compound 34 A solution of I32 mg (0.6 mmol) of mono-CBZ-pi~rerazine in 0.5 mL of CHzCl2 was added to a 0°C solution of 100 mg (0.1 mmol) of compound 33 and $4 p,L (0.6 mmol) of Et3N in 0.5 rnL of CHzCIz. The reaction mixture was sti~xed for 18 hours at room temperature, cooled to 0°C, and acidified with 1 N HCI. The mixture was partitioned between S mL of 1 N HCl and 3 X 5 mL of CHZC12. The cc>mbined organic layers were washed with saturated NaHC03 solution, dried (MgS04), filftered, and concentrated to give 123 mg of white solid. Purification by silica gel chromatography (CH2C12/MeOH) provided 8d mg (65%) of compound 34 as a crystalline solid: mp 64-67°C;

(CDCI3) 8 3.35-3.63 (m, 36H), 3.86 (brd, 4H), 4.13 (brd, 4H), 4.41 (brd, 4H), 5.14 (s, 8H), 7.38 (brd s, 20H), 7.43 (s, 4H); '3C NMR (CDC13) S 43.5, 45.1, 48.4, 62.6, 67.4, 126.9, 128.0, 128.2, 128.5, 136.3, 137.4, 155.1, 171.4; HRMS (FAB) calculated for C68H8°CsN,°O,$ (M+Cs): 1457.4706. Found: 1457.4781.

Compound 34a In a process similar to that described above for compound I 5, compound 34 is treated with 30% HBr/AcOH for 30 min. The resulting I-IBr salt is precipitated with ether.
The solids are collected by centrifugation and washed wil:h ether. The resulting HBr salt is dried in the desiccator overnight and dissolved in HBO. The mixture was stirred at 0°C and sodium bicarbonate added. A solution of bromoacetic anihydride in dioxane is added, and the mixture: stirred at 0°C for I S-20 min. To the mixture is added H20, and the mixture is slowly acidified with I M HZS04 to a pH of 4. The aqueous layer is extracted with EtOAc which was discarded. The aqueous layer is then extracted with 8/2 CHZCIz/MeOH.
The combined organic layers are dried (MgS04), filtered and concentrated to give compound 34a.
IS Example 9 Synthesis of ~ctamer of DEA/PTH Using Core Fropa~;ation Approach A chemical scheme for the preparation of an octarner of DEA/PTH is shown in Figure 16B. Diethanolamine was reacted with the tetrapa~ra-nitrophenylcarbonate compound (compound 33) to yield the octahydroxy compound, compound _35a.
Compound 35a was then reacted withpara-nitrophenylchloroformate to yield the octa para-nitrophenylcarbonate compound (compound 3S). Thepar~a-nitraphenylcarbonate (PNP) group was then converted to a carbamate group by reaction with mono-CBZ-protected piperazine, yielding compound 36. The terminal CBZ-protected amino groups were then converted to the hydrobromide salt of amino group, and further reacted with bromoacetic anhydride to yield reactive bromoacetyl groups at each of l;he termini in compound 36a.
Compound 35a A solution of 100 mg (0. I mmol) of compound 33 i.n 450 p,L of pyridine was slowly added to a 0°C solution of 63 mg (0.6 mmol) of diethanolaa:nine in 150 ~L of pyridine. The mixture was stirred for 3 hours at room temperature and cooled back to 0°C, to yield crude compound 35a, which was used in the next step.
Compound 3S
S
A solution of 443 mg (2.2 mmol) of 4-nitrophenylchloroformate was added to the reaction mixture above, and the mixture was stirred for 18 hours at room temperature. The mixture was then cooled to 0°C, and acidified with 1 N FfCI, and partitioned between 15 mL of 1 N HCl and 2 X 15 mL of CHzCI2. The combined organic layers were dried I O (MgS04), filtered, and concentrated to give 462 mg of wlhite sticky solid.
Purification by silica gel chromatography (CH2C12/MeOH) provided 141 mg (65%) of compound 35 as a crystalline solid: mp 7S-80°C; 'H NMR (CDCl3) 8 3.52-:3.8I (m, 20H), 3.89 (m, 4H), 4. I2 (m, 4H), 4.36-4.59 (m, 20H), 7.42 (m, 24H), 8.30 (m, 16:H).
15 Compound 36 A solution of 61 rng (0.276 mmol) of mono-CBZ-piperazine in 200 ~,L of CHZCIz was added to a 0°C solution of 50 mg (0.023 mmol) of compound 35 and 39 ~,L (0.276 mmol) of Et3N in 200 ~.L of CHzCl2. The reaction mixtwre was stirred for 7 hours at room 20 temperature, cooled to 0°C, and acidified with 1 N. IICI. The mixture was partitioned between 10 mL of 1 N HCl and 3 X 10 mL of CHZC12. The combined organic layers were dried (MgS04), filtered, and concentrated to give 85 mg of yellow solid.
Purification by silica gel chromatography (CHZC12/MeOH) provided 33 rng (51%) of compound 36 as a sticky low melting solid: 'H NMR (CDCl3) 8 3.37-3.72 (m, 84H), 3.84 (m, 4H), 4.03-4.29 25 (m, 20H), 4.35 (m, 4H}, 5.14 (s, 16H), 7.35 {brd s, 40H}, 7.44 (s, 4H}; MS
(MALDI) calculated for C,4°H"ZNaNZZO42 {M+Na): 2856. Found: 2,857.

Compound 36a In a process similar to that described above for compound _I5, compound _36 is treated with 30% HBr/AcOH for 30 min. The resulting fl:Br salt is precipitated with ether.
The solids are collected by centrifizgation and washed with ether. The resulting HBr salt is dried in the desiccator overnight and dissolved in H20. Tlhe mixture was stirred at 0°C and sodium bicarbonate added. A solution of brornoacetic anhydride in dioxane is added, and the mixture stirred at 0°C for 15-20 min. To the mixture is added H20, and the mixture is slawly acidified with 1 M H2S04 to a pH of 4. The aqueous Iayer is extracted with EtOAc which was discarded. The aqueous layer is then extracted with 8/2 CHzCl2/MeOH.
The combined organic layers are dried (MgS04), filtered and concentrated to give compound 36a.
Example 10 Synthesis of Tetramer of DEA/DEG Using Core Propa~zation Approach A chemical scheme for the preparation of an tetrarner of DEAIDEG is shown in Figures I7A and 17B. Diethyleneglycol (from which the "core" is derived) was reacted withpara-nitrophenylchloroformate to yield the di para-nitrophenylcarbonate compound (compound 37). Compound 37 was then reacted with diethanolamine to form the tetrahydroxy compound, compound 38. Compound _38 was then reacted with para-nitrophenylchloroformate to yield the tetra para-nitrophenylcarbonate compound (compound 39}. Thepara-nitrophenylcarbonate (PNP) group was then converted to a carbamate group by reaction with mono-CBZ-protected piperazine, yielding compound _40.
The terminal CBZ-protected amino groups were then converted to the hydrobromide salt of amino group (compound 41~, and further reacted with bromoacetic anhydride to yield reactive bromoacetyl groups at each of the termini in compound 42.

Compound 37 Diethyleneglycol bis-4-nitrophenyicarbonate Pyridine (30.5 mL, 377 mmol) was slowly added 1to a 0°C solution of 5.0 g {47.11 mmol) of diethylene glycol and 23.74 g (118 mmol) of 4-nitrophenylchloroformate in 500 mL of THF. The cooling bath was removed, and the mixture was stirred for 18 hours at room temperature. The mixture was cooled back to 0°C, acidified with 6 N HCI, and partitioned between 400 mL of 1 N HCl and 2 X 400 mL of CHzCl2. The combined organic layers were dried (MgSOa), filtered, and concentrated to give 24.3 g of a white I O solid. Crystallization from hexanes/EtOAc gave I6.0 g ('78%) of compound 37 as a white powder: mp 110°C; 'H NMR (CDC13) 8 3.89 (t, 4H}, 4.50 (t, 4H), 7.40 (d, 4H), 8.26 (d, 4H).
Compound 38 A solution of 2.5 g {5.73 mmol) of compound 37 in 17 mL of pyridine was added' to a 0°C solution of 1.8 g (17.2 mmol) of diethanolamine in :3 mL of pyridine. The cooling bath was removed, and the mixture was stirred for 5 hours at room temperature to yield compound 38, which was not isolated but was used as is in the next step.
Compound 39 The mixture from the previous step was cooled back to 0°C, 40 mL of CHZC12 was added followed by a solution of 11.55 g (57.3 mmol) of 4-~nitraphenylchloroformate in 60 mL of CHZC12, and the mixture was stirred for 20 hours at room temperature.
The mixture was cooled back to 0°C, acidified with 1 N HCI, and partitioned between 300 mL of 1 N
HCl and 2 X 200 mL of CHzCIz. The combined organic layers were dried (MgS04), filtered, and concentrated to give 13.6 g of yellow solid. Purification by silica gel chromatography (CHZC12/MeOH and EtOAc/hexanes) provided 4.91 g (83%) of compound 39 as a sticky amorphous solid: 'H NMR (CDCI3) 8 3.72 (m, 12H), 4.31 (t, 4H), 4.48 (m, 8H), 7.40 (m, 8H), 8.29 (m, 8H).
Compound 40 A solution of 128 mg (0.58 mmol) of mono-CBZ-~piperazine in 1.0 mL of CHZCl2 was added to a 0°C solution of 100 mg (0.10 mmol) of compound 39 and 82 ~,L (0.58 mmol) of Et3N in I .0 mL of CHZC12. The reaction mixture was stirred for I 8 hours at room temperature, cooled to 0°C, and acidified with 1 N HCI. 'The mixture was partitioned between I O mL of 1 N HCl and 3 X 10 mL of CHzCl2. Tlle combined organic layers were washed with saturated NaHC03 solution, dried (MgS04), filtered, and concentrated to give 162 mg of yellow oil. Purification by silica gel chromatography (EtOAc/hexanes followed by CHZCIZ/MeOH) provided 125 mg {95%) of compound 40 as a glassy amorphous solid:
'H NMR (CDCl3) 8 3.36-3.59 (m, 40H), 3.68 (t, 4H), 4.2:Z (m, 12H), 5.16, (s, 8H), 7.36 IS (brd s, 20H); MS (ESI) calculated for C66Hz4NaN,o02~ (M-+-Na): 1376. Found:
1376.
Compound 41 Compound 40 (150 mg, 0.1 I mmol) was dissolvedl in 3 mL of 30% HBr/HOAc.
The mixture was stirred for 30 minutes at room temperature, and the HBr salt was precipitated by addition of EtzO. The precipitate, compound 4I, was washed twice with Et~O and dried under vacuum.
Compound 42 The precipitate, compound 41, was dissolved in 20 mL of HzO. The mixture was brought to pH 12 by addition of 10 N NaOH and extracted with six 20 mL
portions of 4/1 CHZCIZ/MeOH. The combined organic layers were dried (MgS04), filtered, and concentrated to provide the free amine., The free amine w~~s dissolved in 8 mL
of CH3CN, I .5 mL of MeOH was added to improve solubility, and the: solution was stirred at 0°C

while a solution of 114 mg (0.66 mmol) of chloroacetic anhydride in 2 rnL of CH3CN was added. The mixture was stirred at room temperature for 2.5 hours and concentrated to give 107 mg of an oil. Purification by preparative HPLC (1" C18 column, gradient 25-45% B, A = 0.1 % TFA/H,O and B = 0.1 % TFA/CH3CN) provided 44 mg of compound _42 as a viscous oil: 'H NMR {CDCl3) b 3.41-3.80 (rn, 44H), 4.12 (s, 8H), 4.24 {m, 12H); MS (ESI) calculated for C4zH65CI4N,o0" (M+H): 1121. Found: 1121.
Example 11 Synthesis of Octamer of DEA/DEG Using Core Propagation Approach A chemical scheme for the preparation of an octarner of DEA/DEG is shown in Figures 17C and I7D. The tetrapara-nitraphenylcarbonate compound, compound 39, was reacted with diethanolamine to form the octahydroxy compound, compound _43a.
Compound 43a was then reacted withpara-nitrophenylchloroformate to yield the octa para-nitrophenylcarbonate compound {compound 43). Thepara-nitrophenylcarbonate (PNP) group was then converted to a carbonate group by reaction with mono-CBZ-protected piperazine, yielding compound 44. The terminal CBZ-protected amino groups were then converted to the hydrobromide salt of amino group (compound 44a), and further reacted with bromoacetic anhydride to yield reactive brom~oacetyl groups at each of the termini in compound 45.
Compound 43a A solution of 100 mg (0.097 minol) of compound 39 in 450 p.L of pyridine was added to a 0°C solution of 6I mg (0.583 mmol} of dietha.nolamine in 150 p.L of pyridine.
The cooling bath was removed, and the mixture was stirred for 20 hours at room temperature, to yield the crude compound 43a, which was used as is in the next step.

Compound 43 The mixture from the previous step was cooled back to 0°C, and a solution of 431 mg (2.138 mmol) of 4-nitrophenyichloroformate in 4 mL of THF followed by 2 mL
of CHzCI, to improve solubility. The mixture was stirred fo:r 18 hours at room temperature, cooled back to 0°C, acidified with 1 N HCI, and partitioned between 20 mL of 1 N HCl and 2 X 20 mL of CHZCIz. The combined organic layers were: dried (MgS04), f ltered, and concentrated to give 505 mg of yellow solid. Purif cation by silica gel chromatography (EtOAc/hexanes) provided 146 mg (68%) of compound 4:3 as a crystalline solid:
mp 67-69°C; 'H NMR (CDC13) 8 3.50-3.80 (m, 28H), 4.22 (m, 1:2H), 4.43 (m, 1dH}, 7.40 {m, I6H), 8.30 (m, I6H).
Compound 44 A solution of 476 rng (2.16 mmol) of mono-CBZ-piperazine in 2.0 mL of CHZC12 was added to a 0°C solution of 400 mg (0. I 8 mmol) of compound _43 and 300 p,L (2.16 mmol) of Et3N in 2.0 mL of CHZCh. The reaction mixture was stirred for I 8 hours at room temperature, cooled to 0°C, and acidified with 1 N HCI. The mixture was partitioned between 40 mL of 1 N HCl and 3 X 40.mL of CHzCl2. The combined organic layers were washed with 3 X 40 mL of saturated NaHCO~ solution, dried (MgS04), filtered, and concentrated to give 483 mg (97%) of compound 44 as a sticky white solid which was pure enough for use in the next step: 'H NMR (CDCI,) $ 3.36-3.60 (m, 88H), 3.66 (t, 4I-i~, 4.2I
(brd, 28H), 5. i 5, (s, 16H), 7.36 (brd s, 40H).
Compound 44a Compound 44 (150 mg, 0.054 mmol) was dissolved in 2 mL of 30% HBrfHOAc.
The mixture was stirred for 30 minutes at room temperature:, and the HBr salt was precipitated by addition of EtzO. The precipitate was washed twice with Et,O, and dried under vacuum.

Compound 45 The precipitate, compound 44a, was dissolved in :~0 mL of HzO. The mixture was brought to pH L2 by addition of 10 N NaOH and extracted with six 20 mL
portions of 4/1 CHZCI,/MeOH. The combined organic layers were dried (MgS04), filtered, and concentrated to provide the free amine. The free amine was dissolved in 4 mL
of CH3CN, 0.5 mL of MeOH was added to improve solubility, and the solution was stirred at 0°C
while a solution of 1 I2 mg (0.65 mmol) of chloroacetic aylhydride in I mL of CH3CN was added. The mixture was stirred at room temperature for 2 hours and concentrated to give 1 I I mg of an oil. Purification by preparative HPLC (1" CI8 column, gradient 35-55% B, A = 0.1% TFA/H,O and B = 0.1% TFA/CH3CN) provided 20 mg (15%) of compound 45 as a viscous oil: 'H NMR (CDC13) 8 3.40-3.78 (m, 92H), 4.15 (S, 16H), 4.28, (m, 28H).
Example 12 ~nthesis of Tetramer and Octamer of ADPIDEG Using Core Propagation Approach A chemical scheme for the preparation of an octamer of ADP/DEG is shown in Figures 18A and I 8B. The di pares-nitrophenylcarbonate derivative of diethyleneglycol, compound 37 (from which the "core" is derived) was reacted with 2-amino-1,3-propanediol to yield the tetrahydroxy compound, compound 46. Compound _46 was reacted withpares-nitrophenylchloroformate to yield the tetrapara-nitrophenylcarbonate compound (compound 47). Compound 47 was then reacted with 2-amino-1,3-propanedial to yield the octahydroxy compound, compound 47a. Compound 47a was then reacted with para-nitrophenylchIoroformate to yield the octapara-nitrophenylcarbonate compound (compound 48). Thepara-nitrophenylcarbonate (PNP) group was then converted to a carbamate group by reaction with mono-CBZ-protected pip~erazine, yielding compound 48a. The terminal CBZ-protected amino groups were then .converted to the hydrobromide salt of amino group (compound 48b), and further reacted with chloroacetic anhydride to yield reactive chloroacetyl groups at each of the termini in compound 48c.

WO 00134231 f'CT/US99I29339 Compound 46 A solution of compound 37 in pyridine is added t:o a 0°C solution of 3 eq. of 2-amino-1,3-propanediol in pyridine. The cooling bath is removed, and the mixture is stirred for 5 hours at room temperature. Compound 46 can be isolated if desired, however, it is generally more convenient to isolate after forming the 4-nitrophenylcarbonate ester.
Compound 47 The mixture above is cooled back to 0°C, a solution of 10 eq. of 4-nitrophenylchloroformate in 60 mL of CHZC12 is added, and the mixture is stirred for 20 hours at room temperature. The mixture is cooled back to 0°C, acidified with 1 N HCi, and is partitioned between 1 N HCl and CHZCl2. The combined organic layers are dried (MgS04), filtered, and concentrated. Purification by silica gel chromatography provides compound 47.
Compound 47a A solution of compound 47 in pyridine is added to a 0°C solution of 6 eq. of 2-amino-1,3-propanediol in pyridine. The cooling bath is removed, and the mixture is stirred for 20 hours at roam temperature to yield compound 47a., which is used in the next step.
Compound 48 The mixture above is cooled back to 0°C, and a solution of 4-nitrophenylchloroformate is added. The mixture is stirred for 18 hours at room temperature, cooled back to 0°C, acidified with 1 N HCI, and partitioned between 1 N HCI
and CHZCIz. The combined organic layers are dried (Mg;304), filtered, and concentrated.
Purification by silica gei chromatography provides compound 48.

Compound 48a In a manner similar to that for compound 44 above, a solution of mono-CBZ-piperazine in CHZCIz is added to a 0°C solution of compound 43 and Et3N
in CHZCIz. The reaction mixture was stirred for 18 hours at room temper~~ture, cooled to 0°C, and acidified with 1 N HCI. The mixture was partitioned between 1 N HCl and CHZC12. The combined organic layers are washed with saturated NaHC03 solution, dried (MgS04), filtered, and concentrated to give compound 48a, for use in the next step.
Compound 48b In a manner similar to that for compound 44a above, compound _48a is dissolved in 30% HBr/HOAc. The mixture is stirred for 30 minutes at room temperature, and the HBr salt precipitated by addition of Et20. The precipitate is washed with EtzO, and dried under vacuum.
Compound 48c In a manner similar to that for compound 45 above, the precipitate, compound 48b, is dissolved in H20. The mixture is brought to pH 12 by addition of 10 N NaOH
and ' extracted with 4/1 CHZCIz/MeOH. The combined organic layers are dried (MgS04), filtered, and concentrated to provide the free amine. The firee amine is dissolved in CH3CN, MeOH is added to improve solubility, and the solution is stirred at 0°C
while a solution of chloroacetic anhydride in CH3CN is added. The mixture was stirred at room temperature for 2 hours and concentrated to give crude compound 48c, which is purified by preparative HPLC.

Example 13 ~nthesis of Octamer of DEA/PE Using Core Propagation Approach A chemical scheme for the preparation of an octa~mer of DEA/PE is shown in Figure 19. Pentaerythritol (from which the "core" is derived} was reacted with para-nitrophenylchloroformate to yield the tetrapara-nitrophenylcarbonate compound (compound 49). Compound 49 was then reacted with die:thanolamine to form the octahydroxy compound, compound 49a. Compound 49a was then reacted with para-nitrophenylchloroforrnate to yield the octapara-nitrophenylcarbonate compound (compound 50). Thepara-nitrophenylcarbonate (PNP) group was then converted to a carbamate group by reaction with mono-N-BOC-ethylene;diamine, yielding compound 51.
Compound 49 Pentaerythritol tetrakis-4-nitrophenylcarbonate Pyridine (950 p,L, 11.74 mmol) was slowly added to a 0°C solution of 100 mg (0.734 mmol) of pentaerythrital and 1.18 g (5.88 mmol) of 4-nitrophenylchloroformate in I 0 mL of CHzCIz. The cooling bath was removed, and the mixture was stirred for 24 hours at room temperature. The mixtuxe was cooled back to 0°C, acidified with 1 N HCI, and partitioned between 50 mL of 1 N HCl and 2 X 50 mL of CHZC12. The combined organic layers were dried (MgS04), filtered, and concentrated to give 1.123 g of a white solid.
Purification by silica gel chromatography (EtOAc/hexane;s followed by CH,CI,/MeOH) provided 128 mg (22%} of compound 49 as a white crystalline solid: mp 175°C; : 'H NMR
(CDCl3) b 4.61 (s, 8H), 7.40, (m, 8H), 8.30 (m, 8H).
Compound 49a To solution of 120 mg (0.150 mmol) of compound 49 in 1.6 mL of pyridine at 0°C
was added 87 p,L (95 mg, 0.90 mmol) of diethanolamine. The cooling bath was removed, and the mixture was stirred for 7 hours,at room temperature, and cooled back to 0°C, to yield compound 49a, which was used as is in the next step.

Compound 50 A solution of 756 mg {3.75 mmol) of 4-nitrophenylchloroformate in 3 mL of CH~C12 was added the mixture above. The mixture was stirred for 18 hours at room temperature, cooled back to 0°C, acidified with 1 N HCI, and partitioned between 20 mL of 1 N HCl and 2 X 20 mL of CHZC12. The combined organic layers were dried (MgS04), filtered, and concentrated to give 819 mg of sticky yellow solid. Purification by silica gel chromatography {EtOAc/hexanes and CHZCIz/MeOH) provided 134 mg (47%) of compound 50 as a sticky viscous oil with some impurities: 'H NMR (CDCl3) 8 3.69 (m, 16H), 4.31 (s, 8H), 4.4I (m, 16H), 7.39 (m, 16H), 8.25 (m, 16H).
Compound 51 A solution of compound SO is treated with 10 eq, ofmono-N-BOC-ethylenediamine in pyridine and CHZCI2. The mixture is stirred at room terr.~perature until complete as' evidenced by TLC, and partitioned between I N HCl and C:HzCl2. The combined organic layers is dried (MgS04), filtered, and concentrated to give crude product.
Purification by silica gel chromatography (EtOAc/hexanes and CHZCIz/Me:OH) provides compound 51.
Example I4 Solid Phase Synthesis of Tetramer of DEA/DEG Usin :segmental Approach A chemical scheme for the solid phase synthesis of .a tetramer of octamer of DEA/DEG is shown in Figures 20A and 20B. Wang resin, having terminal hydroxy groups, was reacted withpara-nitrophenylchloroformate to yield the para-nitrophenylcarbonate compound (compound 52). Compound _52 was then reacted with diethanolamine to form the dihydroxy compound, compound _52a. Compound _52a was then reacted withpara-nitrophenylchioroformate to yield the dipara-nitrophenylcarbonate compound (compound 52b). Thepara-nitrophenylcarbonate (PNP) group was then converted to a carbamate group by reaction with mono-CB2:-protected piperazine, yielding compound 53. The CBZ-protected compound was then cleaved from the resin, and reacted with diethyleneglycol bis chloroformate (from which the "core" is derived), to yield the tetra-CBZ-protected amino compound, compound 40. The terminal CBZ-protected amino groups may be converted to the hydrobromide salt of amino group, and further reacted with S chloroacetic anhydride to yield reactive chloroacetyl groups at each of the termini.
Compound 52 Wang resin (25 mg, subst. 0.58 mmol/g, 0.0145 mrnol) was washed with CHZCIz.
The resin was suspended in S80 ~,L of CHzCl2, and IS mg (0.145 mmol} of 4-nitrophenylchloroformate was added followed by 97 p,L of pyridine. After gentle agitation of the mixture for 4 hours, the resin was washed with CHzCI2 and dried, to yield compound S2.
1 S Compound 52a The resin was then suspended in 410 pL of CHZCIz, and 71 mg (0.673 mmol) of diethanolamine {410 p.L of a solution of 82.5 mg of diethanolamine dissolved in 493 p.L of pyridine}. After gentle agitation of the mixture for 16 hours, the resin was washed with CH~C12 and dried, to yield compound S2a.
Compound 52b To the resin was added S80 p.L of CHZC12, and to the mixture was added 15.2 mg 2S (0.145 mmol) of 4-nitrophenylchloroformate followed by f7 ~.L of pyridine.
After gentle agitation of the mixture for 4 hours, the resin was washed vrith CHZCl2 and dried, to yield compound S2b.

Compound 53 To the resin was added 410 p.L of CHZCl2, and to the mixture was added 130 p.L
of mono-CBZ-piperazine followed by 410 pL of pyridine. After gentle agitation of the mixture for 18 hours, the resin was washed with CHzCI2 and dried, to yield compound 53.
Compound 54 To the resin was added 1 mL of 10% TFA in CHZC;12, the mixture was agitated for 10 min, and the mixture was f ltered. The TFA treatment 'was repeated twice, and the combined filtrates were combined and concentrated to give 3 mg {35%) of compound _54;
'H NMR (CDCl3) 8 3.13 (m, 4H), 3.48 (m, 8H), 3.80 {m, 4~H), 4.50 (m, 1H), 5.18 {s, 4H), 7.37 (brd s, lOH); MS (ESI) calculated for C3°H4°NSO$ (M-a-H):
598. Found: 598.
Compound 40 To a solution of 2.1 eq. of compound 54 and 2.1 eq. of Et3N in CHZCIz at 0°C is added a solution of 1 eq. of diethyleneglycol bis-chloroforrnate in CHZCI2.
The mixture is stirred fox at room temperature and concentrated to give cnide compound _40 which can be purified by silica gel chromatography.
Example 15 Compound 39b To a solution of 3. I 7 g (3.08 rnmol) of compound 3!3 in 35 mL of CHZCIZ at 0°C was added 2.6 mL of Et3N followed by a solution of 3.26 g ( 18.49 mmol) of mono-N-Boc-ethylenediamine (also referred to as tert-butyl N-(2-aminoethyl)carbamate, Aldrich Chemical Co.) in 30 mL of CHZC12. The mixture was stirred at room temperature for 18 hours, cooled to 0°, and acidified with 1 N HCI, The mixture was then partitioned between 150 mL of 1 N HCl and three 100 mL portions of CHzCl2. 7Che organic layers were combined and washed with three portions of saturated sodium bicarbonate solution, dried (MgS04), f Itered and concentrated to provide 3.17 g of yellow solid.
Purification by silica gel chromatography (step gradient 98/2 to 95/5 to 90/10 CHzCIz/MeOH) provided 2.76 g (80%) of compound 39b as a white solid. 'H NMR (CDCI~) ~ 1.45 {s, 36H), 3.23 (s, I6H), 3.50 (m, 8H), 3.72 (t, 4H), 4.I9 (m, 8H), 4.26 (t, 4H), 5.38 (brd s, 4H), 5.80 (brd s, 2H), 6.00 (brd s, 2H); mass spectrum (ES) m/z calculated for C;46H84NfoOzt (M+Na):
1135.
Found:ll35.
Compound 39c A solution of 1 g (9.42 mmol) of diethylene glycol, in 20 mL of EtOAc was added to a solution of 3.82 g (23.5 mmol) of carbonyldiimidazole in 80 mL EtOAc and the resulting mixture was stirred for 2 hours at room temperature. The :mixture was concentrated to an oily solid, and the product was purified by silica gel chromatography (97/2 CHZCIZ/MeOH) to give 2.04 g (73%) of the bis-imidazolide of diethylene glycol as a white solid: 'H NMR
(CDCI~) 8 3.87 {t, 4H), 4.58 (t, 4H), 7.08 (s, 2H), 7.41 (s, 2H), 8.16 (s, 2H). A solution of 50 mg (0.17 mmol) of the bis-imidazolide of diethylene glycol in 1 mL of CHZCIz was added to a solution of 54 mg (O.SI) mmol) of diethanoIamine and 82 N.L (80.6 mg, 1.02 mmol) of pyridine in 0.5 mL of CHZC12. The mixture was ;stirred at room temperature for four hours, and to the mixture was added a solution of 248 mg (1.53 mmol) of carbonyldiimidazole in 5 mL of CHzCIz. The mixture was .stirred at room temperature for 1.5 hours and concentrated to an oily solid. Purification by silica gel chromatography (98/2 CHZCh/MeOH) provided 103 mg (82%) of the multivalent activated carbonate derivative compound 39c, including minor impurities. The resulting ail crystallized when placed in the freezer: 'H NMR (CDC13) 8 3.71 (m, 12H), 4.32 (m, 4H), 4.59 (t, 8H), 7.10 (s, 4H), 7.43 (s, 4H), $.18 (s, 4H); mass spectrum (ES) m/z (relative intensity) 380 (100), 443 (18), S I2 (2ti), no parent ion observed.

Claims (46)

1. A compound having the structure of one of the following formulae:

wherein:
n is a positive integer from 1 to 10;
y1, y2, and y3 are independently 1 or 2;
J independently denotes either an oxygen atom or a covalent bond;
R c is selected from the group consisting of:
hydrocarbyl groups having from 1 to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, nitrogen, and hydrogen atoms, and having from 1 to 20 carbon atoms;

organic groups consisting only of carbon, oxygen, sulfur, and hydrogen atoms, and having from 1 to 20 carbon atoms;
each G1, G2, and G3 is independently selected from the group consisting of:
hydrocarbyl groups having from 1 to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, nitrogen, and hydrogen atoms, and having from 1 to 20 carbon atoms;
each R N is independently selected from the group consisting of:
hydrogen;
linear or branched alkyl groups having from 1 to 15 carbon atoms;
alkyl groups comprising an alicyclic structure and having from 1 to 15 carbon atoms;
aromatic groups having from 6 to 20 carbon atoms;
heteroaromatic groups having from 3 to 20 carbon atoms;
each Z is independently selected from the group consisting of:
-H
-C(=O)OR CARB
-C(=O)R ESTER
-C(=O)NR A R B
wherein:
each R CARB is organic groups comprising from 1 to about 20 carbon atoms;
each R ESTER is organic groups comprising from 1 to about 20 carbon atoms;
each group -NR A R B is independently selected from the group consisting of:

-NHR A
-NR A R B
-NR AB
wherein each monovalent R A and R B and each divalent R AB is independently an organic group comprising from 1 to 20 carbon atoms, and further comprising a reactive conjugating functional group.
2. A compound according to claim 1, wherein said compound has the structure of Formula I.
3. A compound according to claim 1, wherein said compound has the structure of Formula II.
4. A compound according to claim 1, wherein said compound has the structure of Formula III.
5. A compound according to any one of claims 1 to 5, wherein n is a positive integer from 2 to 4.
6. A compound according to any one of claims 1 to 5, wherein y1, y2, and y3 are each 2.
7. A compound according to any one of claims 1 to 6, wherein J is an oxygen atom.
8. A compound according to any one of claims 1 to 6, wherein J is a covalent bond.
9. A compound according to any one of claims 1 to 8, wherein R C is selected from the group consisting of hydrocarbyl groups having from 1 to 20 carbon atoms.
10. A compound according to any one of claims 1 to 8, wherein R C is selected from the group consisting of:

-CH2-;
-CH2CH2-;
-CH2CH2CH2-;

11. A compound according to any one of claims 1 to 8, wherein R c is selected from the group consisting of organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms.
12. A compound according to any one of claims 1 to 8, wherein R c is:

wherein p is a positive integer from 2 to 20.
13. A compound according to any one of claims 1 to 12, wherein each G1, G2, and G3 is independently selected from the group consisting of hydrocarbyl groups having from 1 to 20 carbon atoms.
14. A compound according to any one of claims 1 to 12, wherein each G1, G2, and G3 is -(CH2)q wherein q is a positive integer from 1 to 20.
15. A compound according to any one of claims 1 to 12, wherein each G1, G2, and G3 is independently selected from the group consisting of organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms.
16. A compound according to any one of claims 1 to 12, wherein each G1, G2, and G3 is:

wherein p is a positive integer from 2 to 20.
17. A compound according to any one of claims 1 to 16, wherein each R N is independently selected from the group consisting of -H, -CH3, and -CH2CH3.
18. A compound according to any one of claims 1 to 17, wherein each Z is -NR A
R B and is independently selected from the group consisting of:

19. A compound having the structure of one of the following formulae:

wherein:
n is a positive integer from 1 to 10;
y1, y2 and y3 are independently a positive integer from 1 to 10;
J independently denotes either an oxygen atom or a covalent bond;
R c is selected from the group consisting of:
hydrocarbyl groups having from 1 to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, nitrogen, and hydrogen atoms, and having from 1 to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, sulfur, and hydrogen atoms, and having from 1 to 20 carbon atoms;
each G1, G2, and G3 is independently selected from the group consisting of:

hydrocarbyl groups having from 1 to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms;
organic groups consisting only of carbon, oxygen, nitrogen, and hydrogen atoms, and having from i to 20 carbon atoms;
each R N is independently selected from the group consisting of:
hydrogen;
linear or branched alkyl groups having from 1 to 15 carbon atoms;
alkyl groups comprising an alicyclic structure and having from 1 to 15 carbon atoms;
aromatic groups having from 6 to 20 carbon atoms;
heteroaromatic groups having from 3 to 20 carbon atoms;
each Z is independently selected from the group consisting of:

-H
-C(=O)OR CARB
-C(=O)R ESTER
-C(=O)NR A R B

wherein:
each R CARB is organic groups comprising from 1 to about 20 carbon atoms;
each R ESTER is organic groups comprising from 1 to about 20 carbon atoms;
each group -NR A R B is independently selected from the group consisting of:

-NHR A
-NR A R B
-NR AB

wherein each monovalent R A and R B and each divalent R AB is independently an organic group comprising from 1 to 20 carbon atoms, and further comprising a reactive conjugating functional group.
20. A compound according to claim 19, wherein said compound has the structure of Formula TV.
21. A compound according to claim 19, wherein said compound has the structure of Formula V.
22. A compound according to claim 19, wherein said compound has the structure of Formula VI.
23. A compound according to any one of claims 19 to 22, wherein n is a positive integer from 2 to 4.
24. A compound according to any one of claims 19 to 23, wherein y1, y2, and y3 are each 2.
25. A compound according to any one of claims 19 to 24, wherein J is an oxygen atom.
26. A compound according to any one of claims 19 to 24, wherein J is a covalent bond:
27. A compound according to any one of claims 19 to 26, wherein R c is selected from the group consisting of hydrocarbyl groups having from 1 to 20 carbon atoms.
28. A compound according to any one of claims 19 to 26, wherein R c is selected from the group consisting of:

-CH2-;
-CH2CH2-;
-CH2CH2CH2-;

29. A compound according to any one of claims 19 to 26, wherein R c is selected from the group consisting of organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms.
30. A compound according to any one of claims 19 to 26, wherein R c is:

wherein p is a positive integer from 2 to 20.
31. A compound according to any one of claims 19 to 30, wherein each G1, G2, and G3 is independently selected from the group consisting of hydrocarbyl groups having from 1 to 20 carbon atoms.
32. A compound according to any one of claims 19 to 30, wherein each G1, G2, and G3 is selected from the group consisting of:

33. A compound according to any one of claims 19 to 30, wherein each G1, G2, and G3 is independently selected from the group consisting of organic groups consisting only of carbon, oxygen, and hydrogen atoms, and having from 1 to 20 carbon atoms.
34. A compound according to any one of claims 19 to 33, wherein each R N is independently selected from the group consisting of -H, -CH3, and -CH2CH3.
35. A compound according to any one of claims 19 to 34, wherein each Z is -NR
A R B
and is independently selected from the group consisting of:

36. A conjugate comprising a compound according to any one of claims 1 to 35 covalently linked to one or more biologically active molecules.
37. A conjugate according to claim 36, wherein said biologically active molecules are selected from the group consisting of oligonucleotides, peptides, polypeptides, proteins, antibodies, saccharides, polysaccharides, epitopes, mimotopes, and drugs.
38. A composition comprising valency platform molecules, wherein each said valency platform molecule comprises at least 2 carbamate linkages and at least 4 reactive conjugating functional groups; and wherein said valency platform molecules have a polydispersity less than about 1.2.
39. The composition of claim 38, wherein said valency platform molecules have a polydispersity less than about 1.07.
40. The composition of claim 38, wherein each said valency platform molecules comprises at least 4 carbamate linkages and at least 8 reactive functional groups.
41. The composition of claim 38, wherein each said valency platform molecule comprises at least 4 identical reactive conjugating functional groups.
42. The composition of claim 38, wherein each said valency platform molecule comprises 2 to 32 carbamate linkages and 4 to 64 reactive functional groups.
43. The composition of claim 38, wherein comprising said valency platform molecules linked via said reactive functional groups to one or more biologically active molecules.
44. A composition comprising valency molecules, wherein each said valency molecule comprises at least two branches and at least four terminal groups;
wherein each said valency molecule comprises at least 2 carbamate linkages;
and wherein said valency molecules have a polydispersity less than about 1.2.
45. The composition of claim 44, wherein said valency molecules have a polydispersity less than about 1.07.
46. The composition of claim 44, wherein said valency molecules comprise at least 4 carbamate linkages, at least 4 branches and at least 8 terminal groups.
CA002353462A 1998-12-09 1999-12-09 Molecular scaffolds acting as templates comprising carbamate linkages Abandoned CA2353462A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11164198P 1998-12-09 1998-12-09
US60/111,641 1998-12-09
US09/457,607 1999-12-08
US09/457,607 US6458953B1 (en) 1998-12-09 1999-12-08 Valency platform molecules comprising carbamate linkages
PCT/US1999/029339 WO2000034231A1 (en) 1998-12-09 1999-12-09 Molecular scaffolds acting as templates comprising carbamate linkages

Publications (1)

Publication Number Publication Date
CA2353462A1 true CA2353462A1 (en) 2000-06-15

Family

ID=26809100

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002353462A Abandoned CA2353462A1 (en) 1998-12-09 1999-12-09 Molecular scaffolds acting as templates comprising carbamate linkages

Country Status (6)

Country Link
EP (1) EP1137628A1 (en)
JP (1) JP2002531541A (en)
KR (1) KR20010093813A (en)
CN (1) CN1333746A (en)
AU (1) AU775925B2 (en)
CA (1) CA2353462A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106588903B (en) * 2016-11-15 2019-11-01 南京正大天晴制药有限公司 Rivaroxaban intermediate impurity, preparation method and isolation and purification method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2412217A1 (en) * 1974-03-14 1975-10-09 Bayer Ag URETHANE POLYOLS CONTAINING POLYALKYLENE OXIDE WITH SULPHONIC ACID GROUP (N)
JPH0761992B2 (en) * 1987-02-06 1995-07-05 武田薬品工業株式会社 Substituted amine derivative
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10772865B2 (en) 2015-03-09 2020-09-15 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11400072B2 (en) 2015-03-09 2022-08-02 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Also Published As

Publication number Publication date
KR20010093813A (en) 2001-10-29
AU775925B2 (en) 2004-08-19
AU2049600A (en) 2000-06-26
JP2002531541A (en) 2002-09-24
EP1137628A1 (en) 2001-10-04
CN1333746A (en) 2002-01-30

Similar Documents

Publication Publication Date Title
US20050226844A1 (en) Valency platform molecules comprising carbamate linkages
AU779887B2 (en) Valency platform molecules comprising aminooxy groups
KR20020059616A (en) Manufacture of polyglutamate-therapeutic agent conjugates
CA2492775A1 (en) Polyalkylene glycol acid additives
EP1592719B1 (en) Conjugation reactions
EP1850877B1 (en) Process for the preparation of alkoxyamine functionalised polyethylene glycols
CA2353462A1 (en) Molecular scaffolds acting as templates comprising carbamate linkages
US6268516B1 (en) Cationic amphiphilic lipids for liposomal gene transfer
JP2005514505A (en) Preparation and use of multi-arm dendritic and functional PEG
CA1215978A (en) Process for preparing 2-carbamoyloxyalkyl-1,4- dihydropyridine derivatives and intermediates useful for the process
JP5612467B2 (en) Method for preparing a hydrolyzable linker based on Fmoc
CA2011277A1 (en) 2-picolylamine derivatives
Voit et al. Perfectly branched polyamide dendrons based on 5-(2-aminoethoxy)-isophthalic acid
EP1846378B1 (en) Cationic lipids for the transfection of nucleic acids
CA2250988C (en) Method of utilizing isocyanate linkages for forming multi-tier cascade polymers
US5703271A (en) Method of utilizing isocyanate linkage for forming multi-tier cascade polymers
US20030119814A1 (en) Novel prodrugs of N-H bond-containing compounds and methods of making thereof
Molina Cabeza Synthesis, Functionalization and Characterization of Dendrimeric Structures. Bioimaging and Tissue Regeneration Applications
KR100217300B1 (en) The preparation of n,n&#39;-dialkyl-3,3&#39;-dithiodipropione amide
KR100273765B1 (en) Method for preparing N- (4-piperidine) benzamide and new active thioester as an intermediate thereof and method for preparing same
Jones et al. Synthesis of multivalent carbonate esters by divergent growth of branched carbamates
AU2002337861A1 (en) Novel prodrugs of N-H bond-containing compounds and methods of making thereof
KR100551096B1 (en) Novel Y-PEG Derivatives and the preparation method thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead